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1 General Introduction 
 
1.1 Overview of the immune system 
 
The term immunity (latin immunitas - freedom from public service) is used to 
describe a feature that is inherent to all kingdoms of life: the capability to resist 
infection by at least some pathogens. Even in procaryotes, mechanisms 
(restriction endonucleases and corresponding methylases) exist that can 
differentiate between self (self DNA) and foreign (foreign DNA), and eliminate the 
latter. The immune system of mammals is much more complex and is the sum of 
all organs, tissues, cells and molecules that are actively involved in the process of 
immunity. As the beginning of the science of immunity, i.e. immunology, 1796 is 
often cited. In this year, Edward Jenner, an English physician, injected an eight-
year old boy with fluid extracted from a pustule derived from relatively harmless 
cowpox (vaccinia). Upon exposition to highly dangerous smallpox (variola), the 
boy survived.  Although Jenner published his observation in 1798, the 
mechanisms required to its explanation were not discovered before the second 
half of the 20th century. Today, immunology may arguably be one of the best 
understood fields of medicine. 
One can subdivide the immune system either topologically into central versus 
peripheral or alternatively, by principles of mechanism, into innate versus adaptive. 
The central immune system is responsible for the generation of highly specialized 
white blood cell (leukocyte) types that encompass most functions of immunity. B-
lymphocytes and other cell types are generated in the bone marrow (or in chicken, 
in the bursa fabricii - hence the term B-lymphocytes), whereas mature T-
lymphocytes are provided by the thymus. The peripheral immune system involves 
organs where these cell types interact with pathogens and derived substances, i.e. 
the spleen, the lymph nodes, and the gut associated lymphoid tissues (GALT). 
The innate immunity system provides a first line of defence for the organism. It can 
react very rapidly (0-96 h) to invading pathogens via preformed effectors and 
effector cells that recognize pathogen-associated molecular patterns (PAMPs) 
which are common to distinct groups of pathogens. Its components are 
inflammatory cells such as granulocytes, macrophages, mast cells, the 
complement system, natural killer cells and subsets of B- and T-lymphocytes, 
6 Unconventional T cells - recombinant MHC molecules pave the way 
 
including γ:δ− and NK1.1+ NK- T cells. During evolution, the innate immune system 
evolved much earlier than the adaptive immune system. However, as the 
receptors involved in innate immunity are of restricted diversity it is not as flexible 
as the adaptive immune system. Additionally, it can not generate an 
immunological memory (see below). 
During an ongoing infection, the adaptive immune system responds later than the 
innate immune system. However, it is much more flexible as it can respond to a 
very high number of foreign structures (antigens) using receptors which 
specificites do not have to be genetically encoded. Furthermore, it provides 
immunological memory, i.e. it mounts an enduring immune response specific for 
the invading pathogen that will ensure more rapid elimination during the next 
encounter. The existence of the immunological memory has been known since 
very long but its mechanism remained unknown. In the 1950s, however, 
Macfarlane Burnet proposed the clonal selection theory. He postulated the 
existence of many different preformed cells in the body with single antigen 
specificity. Upon antigen contact, only those cells expressing, by chance, the 
corresponding specificity would be activated and become clonally expanded, 
leading to immunity against the given antigen. At the time Burnet reported his 
ideas, the cells which may be responsible for the clonal selection in the adaptive 
immune system were entirely unknown. We know today that these are B- and T-
lymphocytes, which represent the humoral and cell-mediated adaptive immune 
system, respectively.  
Humoral immunity (latin umor - moisture, fluid) provides antibody responses 
produced by activated B lymphocytes that can protect against extracellular 
antigens mainly via three mechanisms: neutralization (direct incactivation of 
antigen via antibody binding), opsonisation (engulfment of antigen-antibody 
conjugates by phagocytic cells) and complement activation (indirect inactivation of 
antigen via soluble factors that mediate destruction of antigen-antibody 
conjugates). The cell-mediated immune system can protect from intracellular 
pathogens (viruses, intracellular bacteria) and tumors by the help of T 
lymphocytes. T lymphocytes are able to differentiate between normal and altered 
cells by the use of their T-cell receptor (TCR). Most T cells express one of two 
types of receptor, the α:β or the γ:δ TCR. α:β T cells recognize processed antigen 
presented on major histocompatibility complex (MHC) molecules on the surface of 
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cells (see 1.2 and 1.3). T lymphocytes are also responsible for the coordination of  
many functions of the immune system, including B lymphocytes. To become 
themselves activated, T cells have to recognize antigen first on the surface of 
professional antigen presenting cells (APCs), most notably dendritic cells (DCs). 
These cells have the ability to take up antigen in the periphery, travel to peripheral 
immune organs and present antigen on MHC molecules to T cells. In order to 
perform this task, DCs have to be activated first by pathogenic structures using 
their PAMP-receptors. Therefore, one may say that DCs lie at the interface 
between innate and adaptive immunity. Other professional APCs include activated 
B-lymphocytes and macrophages.  
Although other types of T lymphocytes recognizing different antigens exist within 
the innate immune system, the following text of the general introduction will focus 
on the interaction of α:β T cells recognizing classical MHC molecules. 
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1.2 Antigens recognized by T lymphocytes 
 
T lymphocytes recognize antigen in the context of MHC molecules. This MHC 
restriction was first elucidated 1974 by Peter Doherty and Rolf Zinkernagel, who 
demonstrated that cultures of mouse T cells that killed cells infected with the 
lymphocytic choriomeningitis virus (LCMV) were unable to kill equally infected 
cells that differed only in their expressed MHC molecules [1].  
In humans, MHC molecules are also called Human Leukocyte Antigens (HLA). 
They are encoded on a large, highly polymorphic gene cluster on chromosome six, 
which is usually divided into a class I, II and III antigenic region. So-called classical 
MHC molecules, which are linked to antigen recognition by most T cells of the 
adult body, lie within the class I and II region.  
 
1.2.1 MHC class I molecules 
 
The structure of an MHC class I molecule, HLA-A2, was first resolved using x-ray 
crystallography by the group of Don Wiley [2].  
 
 
Figure 1: ELCH 1.0 Schematic representation of the secondary structure of HLA-A2 (left panel) 
and α-carbon backbone of the α1 and α2 domain (as viewed from the top). From [2]. 
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The human HLA class I molecule was found to have one attached oligosaccharide 
residue (which was known not to be required for cellular expression) and three 
disulfide bonds. The protein is a heterodimer of a highly polymorphic membrane-
spanning α (or "heavy") chain (43 kDa) and the invariable β2-microglobulin (12 
kDa). The heavy chain folds into three domains. While α3 and β2m adopt an 
immunglobulin-like fold, the α1 and α2 domains fold into a single structure 
consisting of two α-helices forming a groove on top of a sheet of eight antiparallel 
β strands. In the original report on the structure [2], the presence of an "extra 
electron density" in that groove was noticed. This was immediately suggested to 
represent a mixture of peptide fragments (antigenic or self) which are presented by 
HLA class I. This material has been subject to considerable biochemical 
investigation [3,4]. Today it is known that MHC class I molecules present peptides 
of generally 8-12 amino acids length within their binding groove. Although peptides 
are mostly bound via their amino- and carboxy-termini, distinct MHC class I 
molecules have binding preferences for distinct peptides, due to preferred binding 
of peptide "anchor amino acids" to residues in the binding groove of the MHC 
molecule. These sites are generally hotspots of MHC polymorphism and polygeny. 
In humans, three classical HLA I loci are described, HLA-A, -B and -C.  
338
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Figure 2: Reported allelic variants of classical HLA loci (including silent mutations, excluding 
pseudogenes) as of December 2004. Derived from the IMGT/HLA Sequence Database 
(http://www.ebi.ac.uk/imgt/hla/).  
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At the time the nature of antigen presented on MHC I molecules was revealed, it 
had been already suggested that these peptides are derived from the cellular 
protein turnover machinery. Indeed, it could be shown that abrogation of the main 
cytosolic protein degradation machinery in eukaryotes, the ubiquitine-proteasome 
system, diminishes MHC class I antigen presentation [5,6]. The constitutive 20S 
proteasome in humans is a 770 kD protein multimer of the structure α7β7β7α7, 
forming four rings of 7 homologous subunits per ring. Its inner rings contain each 
three proteolytically active subunits: β1, β2 and β5. Under the influence of 
immunostimulation via IFN-γ, they are exchanged to the alternative subunits iβ1, 
iβ2 and iβ5 (LMP2, LMP7 and MECL-1), from which two are encoded in the MHC, 
forming the immunoproteasome [7,8], which specificity differs from the 
constitutional proteasome. The 20S proteasome can combine with one or two 19S 
cap subunits to form the 26S proteasome, which may again differ in specificity 
from the 20S proteasome [9]. Proteasomal degradation products were 
biochemically analysed and found to often contain the correct C-terminus for MHC 
I presentation, but to be N-terminally extended [10,11]. These and other 
observations using minigenes [12] led to the hypothesis that the proteasome 
generates N-terminally extended longer precursors of MHC class I ligands. To 
gain access to MHC molecules, peptides need to be transported into the 
endoplasmic reticulum. This ATP-dependent transport is mediated by the 
transporter associated with antigen processing (TAP), a heterodimer of the 
structure TAP1:TAP2 [13]. In humans, TAP can transport peptide of size and 
specificity favourable for MHC ligands [14,15], but does also transport N-terminally 
extended precursors [16]. Extensive experimental evidence now suggests that 
peptide trimming occurs in the cytosol and endoplasmatic reticulum by further 
proteases [17-20]. It should be also noted that different mechanisms of antigen 
processing for MHC I have been suggested, such as peptide splicing reported 
recently [21,22].  
Assembly of the MHC I complex is initiated in humans by association of the ER-
chaperone calnexin with nascent MHC I α chains. After binding to β2-
microglobulin, calnexin is exchanged to another chaperone complex, calreticulin 
and Erp57. This multiprotein complex is associated to TAP via tapasin, where 
peptide binding occurs. Fully folded peptide:MHC (pMHC) complexes are then 
released and transported to the cell surface via the Golgi apparatus [23]. 
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1.2.2 MHC class II molecules 
 
The first structure of an MHC class II molecule by x-ray crystallography, HLA-DR1, 
was also reported by the group of Don Wiley [24]. Overall the structure strongly 
resembles class I, although it consists of two polymorphic chains, α (34 kD, 
membrane-spanning) and β (29 kD) with two domains each. The peptide binding 
cleft is formed by the α1 and β1 domains and accounts for most of the structural 
differences between class I and class II. Due to the more open conformation of the 
latter, binding of longer peptides can be accomodated. Contrary to MHC class I, 
where larger peptides may be bind by "bulging" out of the cleft, class II peptides 
extend out of both ends of the site. Indeed, peptides that bind to MHC class II vary 
greatly in length averaging 15 amino acids [25]. Sequence analysis of these 
peptides revealed that they are usually nested sets representing N- and C-terminal 
extensions of a core sequence. In contrast to MHC class I, binding of peptides is 
mostly mediated via the interaction of its backbone and the binding cleft. Although 
binding pockets also exist for MHC class II, they appear to be more permissive 
than those of MHC class I, and definition of binding motifs for MHC class II alleles 
has proven to be more difficult.  
Due to early observations that inhibition of endosomal pathways abrogated MHC 
class II antigen presentation, it had been suggested since long that MHC class II 
molecules differ from MHC class I in presenting peptides derived from the 
endosomal-lysosomal cellular compartment [26,27]. MHC class II ligands are 
generated by acidic proteases resident in this compartment, most notably 
cathepsins [28]. To be able to reach MHC II molecules, which are formed in the 
endoplasmic reticulum, class II molecules are protected first by binding the trimeric 
invariant chain (Ii). Assembly in the ER is assisted by the chaperone calnexin [29]. 
The nonameric complex (Ii)3(α:β)3 is then targeted via Golgi [30] to the low-pH late 
endosomal compartment where Ii is cleaved by acidic proteases to leave only a 
truncated form of Ii, the class II-associated invariant-chain peptide (CLIP) [31]. 
Exchange of CLIP with MHC class II ligands is assisted by the non-classical MHC 
class II molecule HLA-DM [32]. This molecule also facilitates the continuous 
dissociation and binding of peptides from MHC class II, sometimes called "peptide 
editing", thereby favouring peptide ligands of high avidity. 
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1.2.3 Cross-talk between antigen processing pathways 
 
In the classical view stated above, MHC class I presents intracellular antigens 
derived from the cytosol, whereas MHC class II presents antigens taken up from 
the outside of the cell or from invaders parasiting the endosomal compartment. In 
this simplistic view, these two classes of MHC are then recognized by different T 
cells, CD8+CD4- and CD8-CD4+, respectively. However, indications for strong 
cross-talk between antigen presentation pathways are abundant. It is known that 
naive CD8+ T cells generally need professional APCs for priming. But not all 
intracellular pathogens infect APCs [33]. Furthermore, there have been reports of 
CD8+ T-cell responses to antigens restricted to the extracellular compartment [34]. 
The putative pathway that may allow presentation of exogenous antigens in the 
context of MHC class I is often referred to as cross-presentation, derived terms are 
cross-priming and cross-tolerance. Cross-priming was first reported in experiments 
involving priming against minor histocompatibility antigens that had to be 
transferred to APCs of a different MHC haplotype [35,36]. Since then, the nature of 
the cross-presenting cell, the mechanism of cross-presentation and its biological 
role in vivo have been subject to considerable debate (as reviewed in [37]).  
On the other hand, MHC class II presentation of peptides derived from internally 
synthesized proteins has also been reported and was referred to as the 
endogenous pathway of antigen presentation by MHC class II molecules [38]. Its 
mechanism includes autophagy and is also subject of recent studies ([39] and Jörn 
Dengjel, unpublished data). 
 
 
1.3 T lymphocytes 
 
Even in retrospective, it is rather difficult to define an event that may be considered 
as the "discovery of T cells". In 1942, at a time when the immune system was 
believed to be entirely mediated by phagocytic cells and antibodies, Karl 
Landsteiner investigated the phenomenon of delayed type hypersensitivity 
reaction (DTH). His experiments to transfer it from affected to unaffected animals 
via serum failed, and for unknown reasons he decided to alternatively inject 
isolated white blood cells. He observed that he could render the recipient animal 
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contact sensitive to the same antigen as the donor with this method [40] (luckily, 
the guinea pigs must have been closely related). Spurred by World War II, several 
reports were made in the following years on the nature of cells that mediate tissue 
allograft rejection. In 1944, Peter Medawar made the observation that in contrast 
to autografts, skin allografts of rabbits are rejected in a reaction that involved 
leukocyte invasion of the graft [41]. 
Until the second half of the 20th century, the thymus (possibly from greek θυμοσ - 
life force, soul) remained the last major organ of the body whose function was still 
to be resolved. Between 1961 and 1962, Jaques Miller made several important 
discoveries on the function of this organ. First, he reported that thymectomized 
newborn mice kept under normal conditions invariably died later in life [42], 
showing a marked deficiency in circulating lymphocytes and high susceptibility to 
infection. Second, neonatally thymectomized mice also failed to reject skin grafts 
from unrelated mice [43], focusing the immunologist interest on lymphocytes 
leaving the thymus (later termed T lymphocytes). Finally, he reported a 
comparable role of the thymus after birth by demonstrating the failure of 
thymectomized adult mice to recover immune function after total body irradiation 
[44]. Identification of T cells as a distinct population became possible a few years 
later since the discovery of the mouse θ antigen (later termed Thy-1) [45-47]. 
 
 
1.3.1 The T-cell receptor 
 
Whereas the genetic structure of the T-cell antigenic receptor was already 
determined in the mid-1980s, its spatial structure was described about ten years 
latter by X-ray-crystallography [48-50].  
An α:β T-cell receptor (Figure 3) consists of two different polypeptide chains, the 
membrane-spanning T-cell receptor α and β chains. Each chain consists of two 
immunglobulin-like domains, an amino-terminal variable V and a constant C 
region. The antigen-binding site is formed by the 6 complementary-determining 
region (CDR) loops of the Vα and Vβ regions. On the surface of T cells, the α:β T-
cell receptor is part of a much larger T-cell receptor complex involving several 
accessory molecules, most notably the coreceptors CD8 or CD4, which can 
directly co- interact with MHC I or MHC II, respectively, and the acessory chains 
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Figure 3: Backbone tube representation of the mouse 
2C α:β TCR (top) complexed with the MHC class I 
molecule H2-Kb-SIINFEKL (bottom) [50]. The CDRs of 
the T-cell receptor are indicated in color: 
 
α chain CDR1 light purple 
α chain CDR2 dark purple 
α chain CDR3 yellow 
β chain CDR3 green 
β chain CDR2 dark blue 
β chain CDR1 light blue 
β chain HV4 orange 
 
CD3δ, CD3ε, CD3ζ that are required for the complex intracellular signaling events 
that may result in T-cell activation (reviewed in [51]). 
The genetic structures that underlie the generation of diversity within the α:β T-cell 
receptor repertoire were reported 1984 in a series of remarkable publications from 
the groups of Mark Davis and Tak Mak [52-64]. In strong resemblance to the B-cell 
receptor, diversity of the T-cell receptor is generated through rearrangement of 
many genetically encoded segments (V- and J- elements for Vα, V- D- and J- 
elements for Vβ). This process, which is called somatic recombination, is mediated 
during T-cell development by an enzyme complex that contains the recombination-
activation genes RAG-1 and RAG-2. 
 
 
1.3.2 Development of T cells 
 
The developmental stages of T cells in the mouse and human thymus are believed 
to be relatively well understood (as reviewed in [65,66]). Human T cells derive 
from a common lymphoid progenitor originating from the bone marrow that 
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migrates to the thymus, where further development takes place. Anatomically, the 
thymus consists of many lobules, separated by trabeculae, each being surrounded 
by a capsula and divided into an outer region, the cortex and an inner region 
termed medulla. Progenitor cells entering the thymus are first to be found in the 
junction between cortex and medulla. As they migrate through the cortex they 
differentiate into committed T-cell precursors (pre-T1) expressing for the first time 
T-cell markers such as CD1a, CD2, intracellular CD3ε, CD7 and RAG-1, but 
lacking the cell surface CD3:T-cell receptor complex and the co-receptors CD4 or 
CD8 (hence the term double-negative thymocytes). While these cells proliferate 
and migrate back into the medulla, they differentiate first into CD4+CD8- early 
immature single-positive cells (pre-T2 CD4ISP) and finally into CD4+CD8+ double-
positive thymocytes. During these early development steps, rearrangement of the 
β, γ, and δ loci by the RAG-1:RAG-2 complex occurs. Apparently, committment to 
the α:β or γ:δ lineage is determined by the receptor that is first productively 
expressed. If the β-locus was successfully rearranged in the first place, it pairs 
with a so-called surrogate α chain, pTα, to form the pre-T-cell receptor (β:pTα) of 
double positive α:β committed thymocytes, stopping further rearrangement but 
triggering proliferation. After several rounds of cell division, RAG-1:RAG-2 is 
reexpressed and productive rearrangement of the α locus leads to the 
differentiation into CD4+CD8+ TCRα:β+ cells. However, the majority of TCRα:β+ T 
cells will die by apoptosis, only a small fraction is rescued by a low-affinity 
interaction of the TCR with self-peptide-MHC complexes expressed on thymic 
epithelial cell, a process known as positive selection. T cells also have to undergo 
the process of negative selection that leads to clonal deletion of all thymocytes 
recognizing self-peptide-MHC complexes in the thymus with high avidity. At this 
stage, most α:β T cells lose expression of one coreceptor, becoming either CD4 or 
CD8 single-positive thymocytes. In the classical view, most α:β T cells recognizing 
MHC class I are destined to lose expression of CD4, whereas T cells recognizing 
MHC class II will become CD8 single positive cells. The nature of negative 
seletion, which forms the fundamental basic of central tolerance, has recently 
received renewed interest due to the report of unexpected promiscuous gene 
expression in medullary thymic epithelial cells [67].  
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1.3.3 Homeostasis and priming of naive T cells 
 
Mature T cells leaving the thymus have been termed recent thymic emigrants 
(RTEs) [68]. Human RTEs are characterized by the cell surface phenotype CD1A-
CD3+CD27+CD28+CD45RA+CD45RO-CD62L+CD69-. A more recently described 
marker for RTEs are TCR excision circles (TRECs) [69]. TRECs are episomal 
DNA circles that are generated during excisional rearrangement of TCR genes 
and are non-repetitive, so they become diluted upon T-cell proliferation. 
It is not surprising that RTEs show a very similar phenotype as compared to 
circulating naive T cells. Expression of adhesion molecules like CD62L and 
chemokine receptors like CCR7 contribute to the homing capacity of these 
lymphocytes to the periperal lymphoid organs. Indeed, these cells continuously 
recirculate between the blood and the lymphatic tissues. Although the thymus is 
continuously releasing RTEs throughout much of the life, and T-cell clones expand 
upon antigenic stimulation during infection, the total number of T cells in the body 
remains approximately the same. On the other hand, if a host may become 
lymphopenic, T cells will proliferate vigorously until normal cell numbers are 
reached. These phenomena, called basal and acute homeostasis, have been 
subject to intensive investigations during the last years, especially in the mouse 
system. Mainly two factors have been discussed as a basis for homeostasis, 
competition for cytokines and for self-peptide-MHC complexes.  
 
Table 1: Recent results on the requirements for CD8+ homeostasis in mice. 
 
 naive CD8+ T cells memory CD8+ T cells 
basal homeostasis IL-7 obligatory [70,71]  
self-MHC required [72,73] 
IL-15 obligatory [74] 
self-MHC independent [72] 
acute homeostasis IL-7 obligatory [74] 
IL-15 not involved [71,74] 
self-MHC required [73] 
IL-7 and/or IL-15  
obligatory [74]  
self-MHC independent [75] 
 
Eventually, naive T cells may encounter a pMHC complex that binds to their TCR 
with high avidity. For a productive outcome of this interaction, the pMHC complex 
should be expressed on the surface of an activated professional APC. The inition 
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of the APC:T cell contact will be mostly mediated by adhesion molecule pairs, 
such as ICAM-1:LFA-1, ICAM-2:LFA1, DC-SIGN:ICAM-3 or LFA-3:CD2. Adhesion 
molecules also form the periphery of the so-called immunological synapse [76], 
the highly organised contact spot of the two cells. In the center of this synapse, 
binding of the MHC to the TCR complex takes place. According to the Bretscher-
Cohn two-signal hypothesis, one of the fundaments of immunology, [77], a second 
co-stimulatory signal will be required to activate naive T cells (reviewed in [78,79]). 
Activation requirements of previously primed T cells are less stringent. 
Undoubtedly, the best-characterised and most important example of 
costiumulation is signalling via the CD28:B7 superfamily, most notably via CD28 
on T cells and B7-1 (CD80) or B7-2 (CD86) on the APC. Other examples include 
CD27 on naive T cells and CD70 on APCs. However, once a naive T cell is getting 
activated, it expresses a "second line" of accessory proteins that may sustain 
costimulation, such as 4-1BB, ICOS and OX40, or act as negative regulators, such 
as CTLA-4. These receptors may bind to 4-1BBL, LICOS, OX40L and B7 on the 
APC, respectively. Signalling is also bi-directional, best characterised by activated 
CD4+ T-helper cells that express CD40L, which binds to CD40 on APCs, and 
leads to further activation of the latter [80,81]. The additionally activated APCs are 
prone to express higher levels of MHC and costimulatory ligands, but also more 
inflammatory cytokines, such as IL-12, which in turn may be important as a third 
signal for T-cell priming [82].  
 
There are many reports suggesting that long-lasting activation of CD8+ T cells 
always requires CD4+-mediated help directed against the same antigen (recently 
reviewed by [83]). The cellular mechanism has been allocated to a supposed 
"ménage à trois" of an APC, CD8+ and CD4+ T cell. IL-2 from CD4+ T cells binding 
to the same APC has been suggested to act on the CD8+ T cell, and the above 
mentioned activation of APCs via CD40L from CD4+ T cells was taken as 
evidence. However, recent data has been in conflict with this view [84], so the last 
word on CD4+ help may not have been spoken. 
 
Naive T cells that become successfully primed enter the cell cycle undergoing 
rapid proliferation [85]. They express several activation markers such as CD69, 
CD25 (the IL-2 receptor α chain) and secrete IL-2, an autocrine growth factor for 
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the dividing T cell. Costimulation during priming is essential for the synthesis of IL-
2, antigen recognition without costimulation rather inactivates naive T cells, 
inducing a state of anergy (reviewed in [86]). Proliferating T cells may finally 
differentiate into an array of possible effector T cells (see below). Effector T cells 
express a different repertoire of adhesion molecules that facilitates their homing to 
the periphery, where infection takes place. In addition, a fraction of proliferated T 
cells will form memory T cells that last long after effector T cells have declined.  
 
 
1.3.4 Effector functions of T cells 
 
Effector CD4+ T cells are traditionally divided into TH1 or TH2 helper T cells which 
differ in their cytokine expression (reviewed in [87]): TH1 cells secrete 
predominantly IFN-γ and TNF-α. They activate macrophages, induce B cells to 
synthesize opsonizing antibodies and may be important in the control of cancer via 
antiangiogenesis [88,89]. They can also induce target cell apoptosis via 
expression of FasL. On the other hand, TH2 cells activate B cells by secreting IL-4 
and IL-5, which are then induced to make neutralizing antibodies. It is now 
assumed that the cytokine profile during early infection, as well as the strength and 
duration of antigen during priming determines the differentiation of CD4 T cells into 
TH1 or TH2 effector cells (reviewed in [90]).  
A mucosal subset of CD4+ T cells with immunosuppressive effector functions that 
predominantly secrete TGF-β and IL-10 has been designated TH3 [91]. Similarly, 
CD4+ type 1 T regulatory cells (TR1) have been reported that differentiate in the 
presence of IL-10 and secrete predominantly IL-10 by themselves [92]. Both TH3 
and TR1 are believed to be derived from conventional naive α:β CD4+ T cells 
under tolerogenic conditions.  
CD4+CD25+ cells were originally described as a cell population in mouse spleen 
and lymph nodes with immunosuppressive function [93]. Recently, many groups 
suggested that these cells constitute an unique subset of T cells, termed innate 
regulatory T cells (or simply TReg) distinct from TH3 or TR1 cells that may be 
already generated in the thymus and mediate suppression of other T cells in an 
so-far uncharacterized, cell-contact-dependent manner (as reviewed by [94,95]). 
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Conventional textbook knowledge states that naive CD8+ T cells differentiate into 
cytotoxic T lymphocytes (CTLs) that can rapidly induce apoptosis on target cells 
expressing cognate antigen. For this effector function, T cells rely on several 
mechanisms (reviewed in [96]), most notably perforin and granzymes which are 
stored in lytic granules of the CTL, and expression of FasL. However, CTLs can 
also express cytokines upon activation, particularly TH1-like cytokines such as IFN-
γ and TNF-α, that increase MHC expression on target cells and activate 
macrophages. By the use of these mechanisms, CTLs play a very important role 
for the control of viruses, intracellular bacteria and presumably cancer. CD8+ T 
cells expressing TH1-like or TH2-like cytokines are also sometimes referred to as 
TC1 and TC2, respecitvely [97]. Similar to TR1 CD4+ T cells, regulatory CD8+ cells 
(TR) that suppress immune functions via TGF-β have also been described under 
tolerogenic environments [98]. 
 
 
1.4 Analysis of antigen specific T-cell responses 
 
The ability to analyse T-cell responses against a given antigen is essential. For 
example, in vitro experiments which are aimed at identifying T-cell epitopes always 
call for such assays as an end point. Monitored in vivo immune responses 
occurring during infection, transplantation, autoimmunity or after vaccination 
require determination of T-cell activation, too. The analysis of T-cell responses 
under such circumstances is a special case of or “immune monitoring” or 
“immunomonitoring”. This term has appeared in the literature since 1975 [99] and 
has been used since then for the recording and analysis of patient immunological 
parameters.  
A general problem for the analysis of antigen specific T-cell responses is the 
usually low frequency of T cells occurring against a given antigen (like so many 
areas of biology, a needle-in-a-haystack kind of problem). The frequency of naive 
peripheral T cells against a given antigenic epitope has been estimated between 
4x10-8 and 2x10-5 [100-102] but may increase during T-cell responses up to 6x10-1 
among CD8+ T cells [103]. Any ideal T-cell assay would be a direct assay covering 
this full dynamic range with high linearity. Biological and technical problems arise. 
Naive, effector and memory may display different functions and requirements for 
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activation. Very large quantities of sample material would be necessary, usually 
human peripheral blood, which is not available in unlimited amounts. Additionally, 
for a biological assay, exceptional good signal to noise ratio would be necessary. 
So one does not wonder, although a wide variety of T-cell assays has been 
reported, the "ideal" assay does not yet exist. 
One may divide T-cell assays into functional versus specificity assays. Within 
these two groups, tests can be categorized whether they will directly yield a 
discrete number of positive / negative cells within a sample (single cell based 
assays) or a different overall parameter for a sample (bulk assays). Bulk assays 
may be combined with the principle of limiting dilution, which will then indirectly 
lead to cell number information. 
 
 
1.4.1 Functional T-cell assays 
 
Effector or memory T cells encountering antigen, i.e. cognate pMHC complexes, 
on a target cell, respond by exerting an "effect", which may be proliferation, 
cytokine expression, expression of activation markers, degranulation, target cell 
cytotoxicity and/or trogocytosis. One can exploit these effects by challenging a T-
cell sample in vitro with target cells expressing defined pMHC complexes and 
measuring the effect.  
 
Proliferation assays can be realized as classical incorporation assays such as [3H]-
thymidine [104] or 5-bromo-2'-deoxyuridine (BrdU) uptake [105], which are bulk 
assays that measure proliferation by incorporation of labeled nucleotide analogons 
into genomic DNA.  
Within single cell based proliferation assays, cells are labeled first with a stable 
covalent dye, such as 5-(or 6-)-carboxyfluorescein diacetate, succinimidyl ester 
(CFSE) [106]. After each cell division, CFSE content of the cell will be 
approximately reduced by 50 %. By flow cytometry, number of cells that have 
been divided and are still alive as well as the number of cell divisions can be 
determined. 
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A variety of cytokine expression assays have been reported up to now for the 
detection of antigen specific cells. All these assays can be made specific for 
different cytokines, depending on the expected functionality of the cells. Arguably 
the most important cytokine for the detection of TH1-like responses is IFN-γ which 
is strongly expressed after activation of TH1-like CD8 and CD4 cells and against 
which favourable monoclonal antibodies have been raised in the past. 
Bulk cytokine expression assays on a protein level are classic sandwich enzyme 
linked immunosorbent assays (ELISAs) [107] or similar protein detection assays 
such as the cytometric bead assay [108], which allow simultaneous or 
"multiplexed" detection of several cytokines within one sample. On a mRNA level, 
quantitative reverse transcription polymerase chain reaction (Q-RT-PCR) has 
been exploited as a sensitive bulk method to detect antigen specific T cells [109].  
Single cell based cytokine assays are intracellular cytokine staining [110], cytokine 
capture [111] and enzyme linked immunospot (ELISPOT) assays [112,113]. 
Cellular cytokine staining methods raise the problem that cytokines are usually 
rapidly secreted and diffuse away from the secreted cell. While performing 
intracellular cytokine staining, cells are incubated during antigen challenge with 
specific inhibitors (most often Monensin or Brefeldin A) that are able to block 
cellular secretory pathways and lead to an intracellular enrichment of the cytokine, 
which can be fluorescently labeled after permeabilization and fixation of the cells. 
In cytokine capture assays, cells are labeled beforehand with a "capture matrix", 
i.e. anti-cytokine antibodies non-covalently coupled to the cell surface. After 
stimulation, secreted cytokines are captured on the cell surface and can be later 
stained with a fluorescently labeled second anti-cytokine antibody. As this method 
does not require destruction of the cell, it can be combined with live cell sorting. 
ELISPOT is conceptually very similar to ELISA, albeit on a single-cell level. T cells 
and target cells are coincubated on top of a flat membrane, which is non-
covalently linked to an anti-cytokine antibody. Upon stimulation, cells will secrete 
cytokine, which diffuse slowly and form an invisible cytokine "spot" bound to the 
membrane. After removal of the cells, the spot is visualized by an enzyme linked 
second anti-cytokine antibody that is able to form an insoluble dye from a 
substrate which will precipitate on the membrane. Spots can be counted manually 
or computer-aided. 
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Besides cytokines, activated T cells express other proteins that are not found on 
resting T cells, but which are not secreted. Common activation markers for T cells 
are the surface molecules CD69, CD25 and (for human T cells) HLA-DR. Single-
cell assays have been employed [114] that use flow cytometric staining of these 
molecules for the detection of antigen specific T cells. Such methods are, 
however, hampered by the fact that these molecules are only expressed during 
narrow, distinct time windows and that they are also found on subpopulations of ex 
vivo isolated T cells in the absence of antigen [115]. 
 
Degranulation is a new methodology for the detection of antigen specific cytotoxic 
T lymphocytes. When such cells are activated, cytotoxic granula fuse with the cell 
membrane and release their content to the extracellular environment. Proteins, 
e.g. CD107a/b, which are normally found on the granule membrane become 
transiently located to the cell membrane. This effect, which is strongly associated 
to cytotoxicity, can be exploited to detect and sort antigen specific CD8+ cells [116] 
by a single-cell based assay that employs staining cells during and after activation 
with fluorescent anti-CD107a/b antibodies and subsequent flow cytometry. 
 
Cytotoxicity assays are used to detect target cell lysis by an effector cell, which 
can be a cytotoxic T cell. Among bulk cytotoxicity assays, the oldest assay, but 
which may still be the most common method, is the 51Cr release assay [117]. 
Target cells are labeled by a radiochemical compount, 51Cr(VI)O42-, which is able 
to enter cells through anion transport systems and is subsequently reduced in the 
cytoplasm to 51Cr(III) by agents such as gluthathione. As Cr(III) will reside inside 
the cell, cellular accumulation of 51Cr is greatly facilitated [118]. Labeled target 
cells are then washed and coincubated with effector cells. When cytotoxicity 
occurs, target cell 51Cr will be released from the cell and becomes detectable in 
the supernatant. This method can be modified into a competitive assay by 
including a second, unlabeled, target cell population ("cold target inibition"). 
Disadvantages are the fact that not all target cell types are able to sufficiently 
uptake 51Cr(VI) and the cumbersome handling of radioisotopes. Therefore, 
different target cell release assays have been proposed [119], which measure e.g. 
the release of cytoplasmic proteins. A different method for cytotoxicity involves 
labeling the target cell with a covalent dye such as CFSE and, after coincubation 
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with effector cells, detecting target cell apoptosis and / or necrosis by using 
fluorescent markers and flow cytometry [120]. As this method is unable to give 
direct counts of functional effector cells, it should be taken as a bulk assay. 
However, a new single-cell based functional assay has been proposed to directly 
measure the frequency of antigen specific functional cytotoxic T lymphocytes 
[121]. For this "Lysispot" assay, target cells are transfected with a beta-
galactosidase vector and coincubated with effector cells on top of a flat 
membrane, which is non-covalently linked to an anti-galactosidase antibody. Upon 
lysis, target cells will release beta-galactosidase, which will then form an invisible 
spot on the membrane. After removal of the cells, this spot is visualized by the 
inherent enzymatic activity of beta-galactosidase or by means of an enzyme-linked 
second anti-galactosidase antibody capable of forming an insoluble dye from a 
substrate. Spots are then counted manually or computer-aided. 
 
Trogocytosis is an only recently described phenomenon of all lymphocytes. Within 
minutes during formation of a biological synapse, transfer of cell surface material 
from the antigen presenting cell to the effector cell occurs. The mechanism and 
biological function of this effect are currently unknown [122]. However, it has been 
already exploited to detect antigen presenting human CD8+ cells [123]. In such a 
single-cell based assay, target cells have to be engineered such as that they 
express the cognate HLA molecule coupled to green fluorescent protein (GFP). 
When pulsed with antigen and coincubated with specific T cells, the later aquire 
HLA-GFP from the target cell and become fluorescent, which can be detected by 
flow cytometry. 
 
 
1.4.2 Specificity assays 
 
As opposed to their functionality, antigen specific T cells can also be detected 
solely by the presence of the cognate T-cell receptor on their cell surface. This can 
be achieved via binding of labeled pMHC complexes, pMHC microarrays or 
indirectly via analysis of the T-cell receptor rearrangement. 
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Since recombinant pMHC class I complexes with defined peptide content have 
become technically achievable [124], labeled pMHC complexes were tested as a 
method to detect antigen specific CD8+ T cells directly in a single-cell assay via 
flow cytometry. However, early trials have been hampered by the fast off-kinetics 
of the pMHC:TCR interaction [125]. This problem has been overcome using 
labeled multimerized pMHC complexes [126]. In this report, multimerisation was 
achieved by replacing the transmembrane and cytoplasmic domain of the MHC 
heavy chain with a substrate peptide for the enzyme BirA ligase. After in vitro 
refolding of the three polypeptide chains to their native conformation and 
purification, BirA ligase catalyzes transfer of a biotin molecule to a specific lysine 
epsilon amino acid residue within the substrate peptide sequence [127]. After 
removal of excess biotin, biotinylated pMHC complexes are multimerized via 
streptavidin, an avidin-like protein from Streptomyces avidinii, which exhibits four 
binding sites for biotin with very high affinity [128]. Fluorescent labeling is usually 
accomplished by covalent modification of the streptavidin residue. Although 
stochiometry of the multimeric pMHC / streptavidin complexes derived from such 
protocols is rather poorly defined, they are often called MHC tetramers. Later 
deviations of this method include biotinylated pMHC monochains instead of 
trimolecular complexes [129], MHC dimers [130], MHC pentamers [131] or 
reversible binding pMHC multimers [132]. Later were devised to facilitate sorting of 
"untouched" CD8+ T cells via FACS. Additionally, methods have been employed to 
magnetically enrich antigen specific CD8+ T cells via multimerized pMHC 
complexes [133]. During the last years, labeled pMHC class I complexes have 
shed a new light on T-cell responses, as they offered for the first time a window to 
the whole T-cell response against a given epitope, independent of function. The 
development of class I reagents was not fully paralleled for MHC class II, although 
similar tools were devised [134,135]. This may reflect our limited knowledge of 
CD4 T-cell epitopes, the lower extent of expansion of specific CD4+ T-cell 
precursors compared to their CD8+ counterpart, the heterogeneity of CD4+ TCR 
affinities and/or increased difficulties in synthesizing stable recombinant MHC 
class II reagents. But also for MHC class I multimers, caveats have to be taken 
into account. First, pMHC does not only bind to the α:β T-cell receptor, but also 
interacts with the CD8 / CD4 coreceptor. As a consequence, MHC class I 
multimers and antibodies specific for CD8 can affect each other [136,137]. The 
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MHC-CD8 interaction can lead to peptide independent binding and ultimately false 
positive results. Point mutations have been employed to the MHC molecule as a 
workaround [138,139]. pMHC:TCR interactions are temperature dependent, with 
consequences for staining protocols [140]. Finally, MHC class I molecules are 
known to be ligands for molecules unrelated to the TCR/CD8/CD3 complex, i.e. 
natural killer cell receptors, such as immunoglobulin-like transcripts (ILTs) or killer 
cell immunoglobulin-like receptors (KIRs) [141-143]. pMHC multimer binding to 
non-CD8+ T cells is therefore often observed but frequently mistaken as a 
technical artefact.  
 
pMHC microarrays have only been demonstrated very recently [144]. In this 
report, spots of defined pMHC I multimer complexes were immobilized on a two 
dimensional matrix and incubated with a preparation of T cells. Binding of 
individual T cells specific for the spotted pMHC complexes was then detected 
microscopically. In principle, this test may allow multiplex detection of a large 
number of antigen specificites within one sample. However, it remains to be 
proven whether the sensitivity of this methodology can compete with other 
established T-cell assays. 
 
In principle, analysis of the T-cell receptor rearrangement allows quantitation of 
antigen specific T-cell clones. This is most often achieved by the "Immunoscope" 
approach which employs design of clonotypic primers specific for the TCR 
rearrangements of specific T-cell clones [145]. These primers can then be utilized 
for measuring their frequency by quantitative PCR on blood. Although this bulk 
assay does not result in direct cell numbers, it is very sensitive due to the 
amplification involved in the PCR process. The main disadvantages are a) the fact 
that T-cell clones specific for a given antigen have to be identified and isolated by 
different means beforehand and b) the oligoclonality of most T cell responses. 
Although the Immunoscope has been combined with MHC multimer sorting to 
facilitate isolation of T-cell clones [146], these hinderances have precluded so far 
the routine application of this method. 
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1.4.3 Limiting Dilution Assays 
 
Bulk assays have the disadvantage that they do not result in direct cell numbers. 
However, when a bulk assay has the ability to discriminate between the presence 
or absence of at least one antigen specific T cell, it can be combined with the 
principle of limiting dilution. In this method, a heterogeneous T-cell population that 
contains an unknown frequency of antigen specific cells is diluted to ever smaller 
cell numbers in a multiwell plate. At one point of the dilution, some wells will 
recieve one or more specific T cells, and some wells will not. These wells have 
then to be discriminated by employing the bulk assay. From the resulting data, the 
original frequency of antigen specific cells can be calculated using the statistical 
Poisson distribution function [147,148]. In practice, a powerful amplification step 
has to be included (usually proliferation after in vitro stimulation with antigen) to 
allow detection of single cells in one well. Therefore, this assay is strongly biased 
by detecting only the frequency of those antigen specific cells that have a high in 
vitro proliferation potential and do exert the specific function that is measured by 
the functional assay. So, although it has been employed successfully to compare 
the frequency of antigen specific T cells before and after in vivo priming [149], 
these counts are usually a strong underestimation when compared to frequencies 
determined by direct assays. 
 
 
1.4.4 Comparison of different T-cell assays 
 
When comparing different T-cell assays, one would have to evaluate 
systematically several parameters, such as sensitivity, dynamic range, type of 
information (specificity versus functionality; single cell versus bulk assay), time / 
cost per sample, robustness and weighting them for the specific application the 
assay is required for. Such comparisons have been reported, with varying degrees 
of sophistication [150-152]. Some aspects have emerged for the most common 
methods. Among direct single cell assays, MHC tetramer staining and IFN-γ 
ELISPOT have been reported to be more sensitive (detection limit 10-4 - 10-5) than 
cytokine staining techniques. Among bulk assays, IFN-γ qRT-PCR (having a 
comparable sensitivity as ELISPOT or tetramer staining) appears to be superior to 
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ELISA or 51Cr release techniques. Not surprisingly, the highest sensitivity is 
associated with limiting dilution assays [102]. This is currently the only method 
which is sensitive enough to allow quantification of normal precursor frequencies. 
However, it is also the most laborious and costly method and will result in strong 
underestimation of real frequencies. All assays that involve flow cytometry, 
including MHC tetramer staining, are hampered by the relatively low throughput 
that is technically achievable. Nevertheless, they have a great potential for very 
small trials via their possibility to further characterize the antigen specific cells. 
For medium size or larger trials IFN-γ ELISPOT is so far the most commonly 
applied assay, largely due to the relatively high sensitivity combined with the high 
throughput of this single-cell based assay. 
 
 
1.5 In vitro manipulation of antigen specific T cells 
 
Although methods exist that allow detection and quantification of very low T-cell 
frequencies ex vivo, their subsequent detailled characterisation requires large 
numbers of these cells with high purity. Detection protocols including limiting 
dilution also require in vitro amplification steps. Finally, clinical concepts of 
adoptive immunotherapy [153] have been suggested that involve injection of large 
numbers of previously amplified antigen specific T cells into patients to counteract 
infectious or malignant diseases. Therefore, there is need for methods to amplify 
antigen specific T cells in vitro. Such methods are hampered by the general fact 
that proliferation capacities of most primary tissue cell types, including human T 
cells, are limited and strictly regulated under normal conditions.  
One can categorize these methods in assays to purify antigen specific T cells, 
antigen independent amplification methods and amplification methods that involve 
stimulation by specific antigen. 
 
 
1.5.1 Purification of antigen specific T cells 
 
If it is desirable to separate among a mixed T-cell population those which are 
specific for a given antigen, one has to consider different T-cell detection assays 
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that do not interfere with cellular viability and allow labeling the cell, which is then 
used as a signal to sort cells by FACS or magnetically. Alternatively or additionally, 
one may employ limiting dilution to derive T-cell clones. 
 
FACS or magnetic sorting of living antigen specific cells has been reported first by 
exploiting functional assays after antigen stimulation. For this purpose, 
upregulation of activation markers such as CD25 or CD69 after antigen 
stimulation, cytokine capture assays [111], degranulation assays [116] and 
trogocytosis [123] have been suggested. On the other hand, MHC class I and II 
multimers have been employed to sort antigen specific T cells independent of 
functionality [126,133,138,154]. Lately, reversible binding MHC class I multimers, 
so called streptamers [132] were suggested for sorting of antigen specific T cells, 
as binding of conventional MHC multimers may change the properties of the 
sorted cells. 
 
Cloning by limiting dilution is the oldest method to achieve expanded cell cultures 
of T cells with single specificity [155]. For this purpose, mixed cell populations are 
diluted to very small numbers per well and cultured in the presence of lethally 
irradiated feeder cells, mitogen or antigen. However, it is hampered by drawbacks. 
It is time-consuming as one does need to screen very large numbers of grown 
clones for correct specificity, especially when the precursor frequency was not 
very high (< 10%). Furthermore, T-cell clones may differ significantly in their 
phenotype from each other and from the polyclonal T-cell response found among 
the precursor cells. 
 
 
1.5.2 Antigen independent amplification of T cells 
 
Some substances can induce mitosis in most T cells independent of clonal origin 
and antigen specificity. Their use has greatly facilitated cultivation of T 
lymphocytes. However, in mixed populations, composition may change after 
antigen independent stimulation, as not all subpopulations will divide and survive 
at the same rate. For highly enriched or cloned T-cell population, however, this 
fact becomes less important. Antigen independent amplification of T cells is most 
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often achieved by employing polyclonal mitogens or stimulatory antibodies, usually 
in combination with mitogenic cytokines, most often IL-2. 
 
Most polyclonal mitogens are lectins such as phytohaemagglutinin (PHA) [156], 
concanavalin A (Con A) [157] or pokeweed mitogen [158] that activate leukocytes 
by cross-linking glycoproteins on the cellular surface. The most commonly applied 
polyclonal mitogen for human T cells is PHA, a lectin extracted from the red kidney 
bean (Phaseolus vulgaris). PHA is a tetrameric protein consisting of five isolectins 
(L4E0, L3E1, L2E2, L1E3, L0E4), with the purified isolectin L4E0 (PHA-L or 
leukoagglutinin) being the most potent isoform for lymphocyte activation [159].  
 
Antibodies that can induce T-cell stimulation have been reported, mostly against 
the T-cell receptor complex molecule CD3, often in combination with antibodies 
against costimulatory antigens such as CD28. Antibodies are usually immobilized 
on a solid substrate (cell culture dish, microspheres or even cell lines) to induce 
maximal cross-linking of target structures on lymphocytes [160,161]. More 
recently, such systems have become commercially available. Protocols that invole 
stimulation with anti-CD3 and high doses of IL-2 [162] have been employed in the 
clinic to expand tumor specific autologous T cells to very high numbers sufficient 
for successful adoptive transfer therapies [153]. 
 
 
1.5.3 T-cell amplification by stimulation with specific antigen 
 
In vivo, naive antigen specific T cells are activated by professional antigen 
presenting cells, most importantly dendritic cells, whereas memory T cells can be 
activated by non-professional APCs. When driving antigen specific T cell 
populations into proliferation in vitro, approaches that attempt to mimic nature are 
used. Stimulation of memory T-cell populations with peptide [163], protein or 
encoding nucleic acids mostly employ non-professional antigen presenting cells 
within autologous primary cells, autologous derived B-lymphoblastoid cell lines or 
allogeneic cell lines, which are often defective of antigen processing to avoid 
allostimulation. Nevertheless, antigen presentation in the absence of important 
antigen processing pathways is a well-known phenomenon [164]. 
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Classically, expansion of naive T cells is achieved by using in vitro derived 
professional antigen specific cells such as autologous monocyte derived dendritic 
cells [165] or autologous activated B lymphocytes [166]. Some groups have 
reported the use of other autologous cell types for such in vitro priming 
experiments such as activated T cells, that do also express various costimulatory 
molecules [167]. However, the use of autologous professional antigen presenting 
cells is hampered by the fact that current methods for their isolation/generation are 
expensive, time-consuming, difficult to standardize and can only yield relatively 
low cell numbers. Very different approaches have been employed to overcome 
this obstacle by using artificial antigen presenting cells (aAPCs). Many groups 
have put effort into transfecting allogeneic tumor cells with costimulatory and 
adhesion molecules, such as CD80, 4-1BBL, LFA-3 and ICAM-1. To avoid 
allostimulation in these settings, HLA-deficient cells have been used that were 
transfected with single peptide-HLA complexes [168]. Such cells lines are potent in 
vitro aAPCs, but have to be established beforehand for each given pMHC 
complex. A different approach relies on the use of isolated recombinant pMHC 
complexes. These complexes are coated on a surface, which can be lipid vesicles 
[169], plastic microspheres [170-172], or even HLA deficient cell surfaces [173]. 
Interestingly, it has been suggested that MHC with impaired lateral mobility may 
be more efficient in stimulating the TCR when compared to MHC molecules 
floating in a lipid bilayer [173]. aAPCs have been used in the past to study the 
biology of T-cell activation [82,171,173,174]. 
It has been reported that pMHC density during priming will strongly influence the 
avidity of the resulting T cell population [175]. As a part of this dissertation, the 
author investigated such a system with the ability to control pMHC-density, 
predetermining T-cell avidity. 
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Cytotoxic CD8 T cells are key effectors in the immunotherapy of malignant and 
viral diseases. However, the lack of efficient methods for their in vitro priming and 
expansion has become a bottleneck to the development of vaccines and adoptive 
transfer strategies. Synthetic artificial antigen presenting cells (aAPCs) are now 
emerging as an attractive tool for eliciting and expanding CTL responses. We 
show that by controlling the MHC density on aAPCs, high or low avidity tumor-
directed human CTL lines can be raised effectively in vitro if costimulation via 
CD28 and IL-12 is provided. Compared to low avidity CTL lines, high avidity CTLs 
need 100-1000 fold less peptide for activation, bind more MHC tetramers, and, as 
expected, are superior in recognizing tumor cell lines expressing antigen. We 
believe that the possibility to raise antigen specific T cells with predetermined 
avidity will be crucial for the future use of aAPCs in immunotherapeutical settings. 
 
 
 
 
 
52 Unconventional T cells - recombinant MHC molecules pave the way 
 
Introduction 
 
CD8 T cells play a central role in the host defense against viral infections and are 
thought to be key effectors in immunotherapy of malignant diseases. There are 
two main reasons to elicit and expand CTLs in vitro. First, following "reverse 
immunology", candidate T cell epitopes are first identified and their 
immunogenicity validated subsequently (1). Second, for adoptive transfer, large 
numbers of antiviral or antitumor CTLs are expanded ex vivo (2). However, the 
currently applied approaches to elicit primary in vitro CTL responses usually 
involve differentiation of DCs from the patient's blood, which is time-consuming, 
expensive and limited by the obtainable cell numbers. 
It would, therefore, be highly desirable to have artificial antigen presenting cells at 
one's disposal for in vitro experiments. Although some studies have used tumor 
cell lines transfected with MHC:peptide complexes and costimulatory molecules 
for this purpose (3), the most consequently controlled aAPC would involve coating 
of synthetic surfaces, usually cell-sized plastic microspheres, with purified MHC 
plus costimulatory molecules. This is basically a very old idea (4) and several 
groups have relied on it in order to investigate the events that lead to the activation 
of T cells, mostly in the mouse system (5, 6, 7). Soluble MHC reagents were also 
used for this purpose (5), but found to be less potent when directly compared to 
immobilized MHC. Yet, it was only very recently (8) that aAPCs were shown to be 
able to fully induce in vitro priming of human CD8 T cells and to sustain long term 
cellular proliferation, as required for any immunotherapeutical approach. This last 
study, however, used "empty" HLA-Ig fusion proteins coated on microspheres and 
subsequent peptide loading. The efficiency of this process, and thus the functional 
antigen density on aAPCs, will strongly depend on the affinity of an individual 
peptide to the MHC molecule. This precluded an easy control of the number of 
MHC:peptide complexes on the aAPC. It is known, however, that the antigen dose 
will influence the avidity of the responding T cell population (9), with high avidity 
CTLs being superior in adoptive transfer experiments. 
In this study, we rely on preformed MHC:peptide complexes coupled by 
biotin:streptavidin biochemistry to the surface. This systems allows the exact 
control of the MHC density on aAPCs which enables us to selectively elicit high- or 
low avidity antigen specific CTL responses with high efficiency from healthy 
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human individuals. Furthermore, we identify the factors that are necessary for 
successful in vitro priming with aAPCs. 
 
Materials and Methods 
 
Peptides, recombinant MHC molecules, fluorescent tetramers and MHC coated 
microspheres 
Peptides in this study (10, http://www.syfpeithi.de/) were synthesized using 
standard Fmoc-chemistry. The peptide library consisted of an approximately 
equimolar mixture of 6912 nonapeptides with the structure Y, L/M, A/I/L/Y, E/G/P, 
G/K/L, I/V/L, A/V/P/H, E/K/S/T, V/L. Biotinylated recombinant A*02 molecules and 
fluorescent MHC tetramers were produced as described previously (11). The 
costimulatory mouse IgG2a anti human CD28 Ab 9.3 (12) was biotinylated using 
Sulfo-N-Hydroxysuccinimidobiotin as recommended by the manufacturer (Perbio 
Science, Bonn, Germany). As a negative control, biotinylated mouse IgG2a Ab 
G155-178 (Becton Dickinson Biosciences, Heidelberg, Germany) was used. For 
generation of aAPCs, 5.6 µm diameter streptavidin coated polystyrene particles 
with a binding capacity of 0.064 µg biotin-FITC/mg microspheres (Bangs 
Laboratories, Fishers, Illinois/USA) were resuspended at 2 × 106 particles/ml in 
buffer containing biotinylated MHC and Abs at indicated concentrations and 
incubated at room temperature for 30 min. 
 
Antigen-specific in vitro stimulation of human CD8 T cells 
PBMCs were isolated from fresh buffy coats using standard gradient separation. 
When indicated, untouched CD8 T cells were MACS enriched by negative 
depletion (Miltenyi Biotec, Bergisch Gladbach, Germany). 
To compare DC to bead stimulations, monocyte derived human DCs were 
generated as previously described (13) and activated with 10 ng/ml human TNF-α 
(R&D Systems, Wiesbaden, Germany) + 1 µg/ml human prostaglandin E2 (Sigma-
Aldrich, Taufkirchen, Germany) for 2-3 days. Mature DCs were predominantly 
CD14- CD40+ CD80+ CD83+ CD86+ and HLA-DRhi (data not shown). For 
restimulations after priming with DCs, cryopreserved autologous PBMCs were 
used. 
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In vitro stimulations were initiated in 24 well plates with 5 × 106 responder cells 
plus 1 x 106 beads or 1 x 106 irradiated APCs per well in 1.5 ml T cell medium 
which consisted of RPMI 1640 containing 25 mM HEPES (Gibco/Invitrogen, 
Karlsruhe, Germany) supplemented with 10 % heat inactivated human AB serum 
(CC pro, Neustadt/W., Germany), 2 mM L-glutamine, 50 U/ml penicillin, 50 µg/ml 
streptomycin and 20 µg/ml gentamycin (all BioWhittaker/Cambrex Bio Science, 
Verviers, Belgium). If not stated otherwise, 5 ng/ml human IL-12 p70 (R&D) was 
added with APCs or microspheres. After 3-4 days coincubation at 37 °C, fresh 
medium and 20 U/ml human IL-2 (R&D) was added and cells were incubated for 
3-4 days. This stimulation cycle was repeated twice. 
 
Antigen specific T cell enrichment and expansion 
FACS sorting of bead stimulated cells was performed on a FACSVantage after 
staining with PE tetramers and Abs CD8-APC clone SK1 and CD4-FITC (BD). 
Alternatively, bead stimulated cells were restimulated with irradiated T2 cells 
pulsed with 5 µM peptide as described above and IFN-γ+ cells were enriched by 
MACS (Miltenyi). 
Sorted cells were cultured in the presence of 5 × 105 cells/ml irradiated fresh 
allogenic PBMCs, 5 × 104 cells/ml irradiated LG2-EBV cells, 150 U/ml IL-2 and 0.5 
µg/ml PHA-L (Roche Diagnostics, Mannheim, Germany). Cells were further 
expanded in T-cell medium containing 150 U/ml IL-2. 
 
Cell surface / intracellular cytometric analysis 
Tetrameric analyses were performed with fluorescent MHC tetramers plus Abs 
CD4-FITC and CD8-PerCP clone SK1 on a four-color FACSCalibur (BD). Total 
specific cell numbers per sample were calculated by FACS analysis as follows 
after adding a defined number of microspheres to each sample: (specific cells 
counted) × (microspheres added) / (microspheres counted). 
Intracellular cytometry was performed using a Cytofix/Cytoperm Plus kit with Abs 
CD4-FITC, IFN-γ-PE + CD8-PerCP and analysed on a FACSCalibur cytometer 
(BD). 
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Cytotoxicity assay 
Cytotoxicity was tested in a standard 4 h 51Cr release assay using 3000 target 
cells per well. % specific lysis was calculated as follows: (experimental release - 
spontaneous release) / (total release - spontaneous release) × 100. 
 
Results and Discussion 
 
MHC / anti-CD28 coated microspheres are powerful tools for in vitro priming 
Streptavidin linked 5.6 µm polystyrene microspheres could be easily coated with 
biotinylated MHC molecules and costimulatory anti-CD28 Ab. Moreover, labeling, 
as indicated by immunofluorescence, remained almost constant over a storage 
period of 4 weeks (data not shown). Therefore, such particles have immense 
practical advantages over the use of DCs, which can only be generated in limited 
amounts in a time-consuming manner. 
To test the capacity of beads as APCs, human CD8 T cells were stimulated for 
three 7-9 day rounds in the presence of IL-12 with beads coated with anti-CD28 
Ab plus 10 nM A*02 bound epitopes derived from a viral antigen (CMV pp65), a 
modified self antigen (Melan-A) or a tumor derived self antigen (MET proto-
oncogene). As determined by tetramer analysis, stimulation with beads led in all 
cases to a specific CTL expansion with the correspondent specificity (Fig. 1, 
middle panel). There was no staining with an irrelevant tetramer (Fig. 1, right 
panel). When stimulated with beads containing irrelevant MHC molecules, a 
specific tetramer+ population was visible only in the case of the virus recall antigen 
(Fig. 1 left panel, the donor in this experiment was HCMV seropositive). The 
stimulation with the modified self antigen from Melan-A was especially efficient, 
which was also confirmed in experiments with PBMCs from different donors (later 
figures and data not shown). This is consistent with the common observation of 
relatively high precursor frequencies in the blood of healthy A*02+ donors against 
this peptide. However, as these cells appear to be naive (14) and require 
professional APCs to be expanded in vitro (15), our findings indicate that beads 
were capable of efficient in vitro priming. 
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FIGURE 1.  Tetrameric analysis of microsphere driven expansions. Enriched CD8 
T cells of one A*02+ healthy donor were stimulated 3 times with beads coated in the presence of 10 
nM CD28 Ab plus either 10 nM of an irrelevant A*02 complex (left panel) or A*02 refolded with 
indicated antigens (middle and right panel). All T cell lines were surface stained with CD8-PerCP 
Ab, cognate tetramer-PE (left and middle panel) and irrelevant A*02/ILKEPVHGV tetramer-APC 
(right panel). Percentage of tetramer+ cells among CD8+ lymphocytes is indicated in each plot. 
 
 
Microsphere expanded CTLs are functional 
The expanded T cells were functional, since they specifically expressed IFN-γ 
upon restimulation with peptide, as indicated by intracellular cytokine staining. 
Interestingly, this was also the case when beads were used for CTL priming that 
were coated with an A*02/peptide library, indicating that aAPCs may also be 
useful for stimulating with complex antigen mixtures (data not shown). 
To investigate the cytotoxic capabilities of expanded CD8 T cells, fractions from T 
cell lines were sorted and subsequently expanded using mitogen and IL-2. T cells 
proliferated strongly for at least 3 months under such conditions (data not shown). 
Specific cytotoxicity was shown for all tested CTLs and was confined to the 
tetramer+ or IFN-γ+ fraction (Fig. 2). 
 
CTL priming by low MHC density aAPCs requires costimulation and IL-12 
These data indicated that bead expanded CTLs were antigen specific and 
functional. However, several of these CTL lines did not recognize target cells  
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FIGURE 2.  Cytotoxic activity of sorted fractions derived from microsphere 
expanded T cell lines. Enriched CD8 T cells of one A*02+ healthy donor were stimulated 3 times 
with beads labeled in the presence of 10 nM CD28 Ab plus 10 nM of A*02 refolded with either the 
viral peptide NLVPMVATV (A-E), the modified self peptide ELAGIGILTV (F), the self peptide 
YVDPVITSI (G) or a 6912 peptides library (H). The unsorted T cell line (A), the tetramer+ sorted 
cells (B, F, G), the tetramer- sorted cells (C), the IFN-γ+ sorted cells (D, H) or the IFN-γ− sorted cells 
(E) were expanded using mitogen as detailed in Materials and Methods. Specific killing of T2 cells 
loaded with 5 µM cognate peptide (filled circles) or irrelevant peptide (open circles) is shown. 
Cognate peptide was always the peptide or peptide library used for priming. 
 
 
endogenously processing antigen (data not shown). As an explanation, we 
speculated that beads coated with 10 nM MHC (high density beads) as used for 
the above experiments may lead to the preferential expansion of low avidity CTLs. 
To test this hypothesis, we titrated the specific MHC molecules during bead 
coating. Efficient expansions were still observed using 100 fold less of the specific 
MHC molecules (low density beads) than for above experiments (Fig. 3A, left plot). 
The results were similar when total MHC concentrations were kept constant by 
adding an MHC library (Fig. 3A, right plot) as a "filler". 
All stimulations described above were performed in the presence of CD28 Ab on 
aAPCs and exogenous IL-12. To identify obligatory factors for priming, we varied 
stimulation conditions (Fig. 3B). Using high density beads, T cell lines could be 
generated even in the absence of costimulatory CD28 Ab or exogenous IL-12, 
although efficiency was greatly reduced when both were missing. For low density 
beads, however, the presence of CD28 Ab as well as exogenous IL-12 was 
obligatory for successful in vitro priming. To compare efficiency with a well 
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established protocol, this was done in parallel with one stimulation by peptide 
pulsed autologous mature DCs and restimulations by autologous peptide pulsed 
PBMCs. Compared to stimulations by DCs / PBMCs, MHC coated high or low 
density beads were at least as efficient or even superior, especially in terms of 
total numbers of specific cells present. Exogenous IL-12 p70 also enhanced CTL 
responses initiated by DCs + PBMCs, which is well in accordance to previous 
studies describing importance of IL-12 p70 in CD8 T cell priming (16). These data 
support a 3 signal model for the priming of human CD8 T cells that has been 
suggested previously for mice (7). Nevertheless, signals 2 + 3 (ligation of 
costimulatory receptors as CD28 and inflammatory cytokines as IL-12) may 
become redundant in the presence of an extremely strong signal 1, as shown 
previously for mice (6). 
During tetramer analysis, we noted that CTLs generated by low density beads 
bound higher amounts of MHC tetramers (Fig. 3C). According to some previous 
studies, this could indicate higher avidity of CTLs (17), although this may not 
always be the case (18). 
 
 
 
 
 
 
FIGURE 3.  Expansion of CD8 T cells using different MHC densities. A, PBMCs of 
one A*02+ healthy donor were depleted from adherent cells and stimulated 3 times with beads 
labeled in the presence of 10 nM CD28 Ab plus varying concentrations of A*02/ELAGIGILTV (left 
panel), optionally with the addition of A*02/library to reach a constant MHC concentration of 10 nM 
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(right panel). Shown percentage of specific tetramer+ cells among CD8+ CD4- lymphocytes in 1 
representative out of 3 independent experiments from different donors was determined by staining 
cells with CD4-FITC, CD8-PerCP, cognate tetramer-PE and irrelevant A*02/ILKEPVHGV tetramer-
APC. B, PBMCs of another A*02+ donor were depleted from adherent cells and stimulated 3 times. 
APCs were either autologous DCs and PBMCs (d) or beads (b). 5 ng/ml IL-12 p70 was added (+) 
or ommitted (-) at each stimulation. Abs coated on beads were 10 nM CD28 Ab (+) or 10 nM IgG2a 
control Ab (-). DCs were pulsed with 5 µM (solid bars), 500 nM (dashed bars) or 0 M (open bars) 
peptide ELAGIGILTV. MHC coating on beads with A*02/ELAGIGILTV was 10 nM (solid bars), 100 
pM + 10 nM A*02/library (dashed bars) or only 10 nM A*02/library (open bars). Cells were stained 
with Abs CD4-FITC, CD8-PerCP, cognate tetramer-PE and irrelevant A*02/ILKEPVHGV tetramer-
APC. Bars represent mean and SD of the percentage of specific tetramer+ cells among CD8+ CD4- 
lymphocytes from 3 stimulations. The bar belonging to stimulation with 10 nM A*02/ELAGIGILTV, + 
IL-12 and - CD28 Ab was derived from only 2 stimulations. Numbers above each bar indicate mean 
absolute number of specific tetramer+ CD8+ CD4- lymphocytes per well as described in Materials 
and Methods. C, Tetramer stainings of two T cell lines marked in (A) with asterisks. Plots are gated 
on CD4- lymphocytes. Numbers in each plot represent mean PE tetramer fluorescence of cells in 
the upper right quadrant. 
 
 
MHC density during priming influences avidity of resulting CTLs 
To clarify the question of the avidity of CTLs primed by high or low density beads, 
the amount of antigenic peptide was titrated on target cells in a standard 51Cr 
release assay (Fig. 4A). The T cell line generated with high density beads needed 
approximately 10 nM of peptide for recognition whereas the line generated with 
low density beads was of much higher avidity and needed only picomolar amounts 
of peptide for an efficient recognition. Therefore, the antigen density of aAPCs 
influenced the overall avidity of the responding T cell population. As we used 
"filler" MHC molecules on the bead surface to ensure a constant overall MHC 
density, this effect is likely due to less cognate antigen recognition and not due to 
less CD8 binding. The most ready explanation for this finding is that the naive CD8 
T cell precursor pool consisted of different clones with a broad spectrum of 
avidities. High avidity clones are likely to be rarer for a given MHC:peptide 
complex. When stimulating with a low determinant density, only the high avidity 
clones will proliferate. A high antigen dose will lead to the stimulation of many low 
and few high avidity clones. Furthermore, high avidity clones may be overtly 
stimulated by high antigen densities and thus die due to exhaustion effects. 
Overall, these processes would explain the observed results. 
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FIGURE 4.  Cytotoxic analysis of CD8 T cells expanded with different MHC 
densities. A, PBMCs of one A*02+ healthy donor were depleted from adherent cells and stimulated 
3 times with beads labeled in the presence of 10 nM CD28 Ab plus A*02/ELAGIGILTV at a 
concentration of 10 nM (circles), 1 nM (squares) or 100 pM (triangles) with addition of A*02/library 
to reach always a total MHC concentration of 10 nM. T cell lines were incubated with 51Cr labeled 
T2 cells loaded with varying amounts of peptide ELAGIGILTV at a constant E:T ratio of 4:1 based 
on the number of tetramer+ CD8+ CD4- cells. B-G, Enriched CD8 T cells of another A*02+ healthy 
donor were expanded by 3 stimulations with beads labeled in the presence of 10 nM CD28 Ab plus 
A*02/ELAGIGILTV at a concentration of 10 nM (filled circles), 100 pM (triangles) or 0 M (open 
circles) with addition of A*02/library to reach always a total MHC concentration of 10 nM. T cell 
lines were incubated with varying 51Cr labeled target cell lines at indicated total E:T ratios. 
Frequency of tetramer+ CD8+ cells in both A*02/ELAGIGILTV stimulated CTL lines was 40 %. 
Target cell lines were Melan-A- A*02+ JY cells pulsed without (B) or with (C) 5 µM peptide, a Melan-
A+ A*02+ cell line from our dermatology department without (D) or with (E) 5 µM peptide, or Melan-
A+ A*02+ MeWo cells without (F) or with (G) 5 µM peptide. 
 
 
Finally, we tested whether bead generated T cell lines could also recognize tumor 
cells expressing Melan-A and A*02 (Fig. 4B-G). One of such tumor cell lines was 
solely recognized (Fig. 4D) and one other cell line was much better recognized 
(Fig. 4F) by T cells primed with low density aAPCs. Recognition was specific, as 
shown by an irrelevant T cell line from the same donor (Fig. 4B-G) and an 
irrelevant Melan-A- A*02+ target cell line (Fig. 4A). 
 
Concluding remarks 
By controlling the surface density of MHC molecules on coated microspheres, we 
were able to prime at will high or low avidity tumor directed human CD8 T cells in 
vitro. Since our method is highly efficient, it could be useful for clinical tumor 
immunotherapy. MHC coated microspheres provide the most rigorously controlled 
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antigen presenting "cells" available and are a powerful tool that allows new 
insights in key parameters necessary for effective T cell responses. 
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Supplementary material for Walter S et al: Cutting Edge: Predetermined 
avidity of human CD8 T cells expanded on calibrated MHC / anti CD28 coated 
microspheres (not included in publication) 
 
Materials and Methods 
 
Cells 
The TAP-deficient cell line T2 (HLA-A*0201low) (ATCC # CRL-1992), the EBV-
transformed lymphoblastoid B cell lines JY (HLA-A*0201+ Melan-A-) (ECACC # 
94022533) and LG2-EBV (HLA-A*0201-) (1), the melanoma cell line MeWo (HLA-
A*0201+ Melan-A+) (ATCC # HTB-65) and a melanoma cell line from the 
Department of Dermatology, University of  Tübingen (HLA-A*0201+ Melan-A+) 
were used in this study. HLA typed fresh buffy coats were provided by the blood 
bank, University of Tübingen, as approved by the local ethical committee. 
 
Peptides, recombinant MHC molecules, fluorescent tetramers and MHC coated 
microspheres 
Peptides for MHC refoldings and cellular assays were synthesized using standard 
Fmoc-chemistry. Peptides in this study were NLVPMVATV from HCMV pp65 495-
503 (2), ILKEPVHGV from HIV-1 RT 476-484 (3), ELAGIGILTV as a modification 
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from  Melan-A/MART-1 26-35 (4, 5), YVDPVITSI from MET proto-oncogene 654-
662 (6) and an approximately equimolar library of 6912 nonapeptides with the 
structure Y, L/M, A/I/L/Y, E/G/P, G/K/L, I/V/L, A/V/P/H, E/K/S/T, V/L. 
Biotinylated recombinant HLA-A*0201 molecules lacking the transmembrane 
domain and being biotinylated at the carboxy terminus of the heavy chain were 
produced as previously described (7, 8). Fluorescent tetramers were generated by 
coincubating biotinylated HLA-A*0201 with streptavidin-PE or streptavidin-APC 
(Molecular Probes, Leiden, The Nederlands) at a 4:1 molar ratio. 
The purified costimulatory mouse IgG2a anti human CD28 Ab 9.3 (9) was 
chemically biotinylated using Sulfo-N-hydroxysuccinimidobiotin under conditions 
recommended by the manufacturer (Perbio Science, Bonn, Germany). As a 
negative control, irrelevant biotinylated mouse IgG2a Ab G155-178 (Becton 
Dickinson Biosciences, Heidelberg, Germany) was used. Microspheres used were 
5.60 µm diameter streptavidin coated polystyrene particles with a binding capacity 
of 0.064 µg biotin-FITC/mg microspheres (Bangs Laboratories, Fishers, 
Illinois/USA). For microsphere handling, a 0.2 µm sterile filtered  PBS/BSA/EDTA 
buffer consisting of of PBS (BioWhittaker/Cambrex Bio Science, Verviers, 
Belgium) supplemented with 0.5 % protease-free BSA and 2 mM sodium EDTA 
(both Sigma-Aldrich, Taufkirchen, Germany) was used. For coupling to biotinylated 
molecules, microspheres were washed and resuspended at 2 × 106 particles/ml in 
buffer containing biotinylated MHC and / or antibodies at described concentrations. 
Binding was allowed at room temperature for 30 min while agitating. Coated beads 
were washed three times, resuspended in above buffer and stored for up to 4 
weeks at 4 °C before use. Bead coating was assayed with F(ab')2 fragment goat 
anti mouse IgG + IgM PE (Jackson ImmunoResearch, West Grove, 
Pennsylvania/USA) and anti human β-2-M R-PE (Cymbus Biotechnology, 
Chandlers Ford, UK) in a standard immunofluorescence experiment. 
 
 
Antigen-specific in vitro stimulation of human CD8 T cells 
PBMCs were isolated from fresh buffy coats using standard gradient separation 
medium (Linaris, Wertheim-Bettingen, Germany or PAA Laboratories, Linz, 
Austria). When indicated, untouched CD8 T cells were magnetically enriched by 
negative depletion using a CD8 T cell isolation kit (Miltenyi Biotec, Bergisch 
Unconventional T cells - recombinant MHC molecules pave the way 65 
 
Gladbach, Germany) according to the manufacturer's conditions, which resulted in 
a purity of CD8+ TCRαβ+ cells of  more than 80%.  
To compare dendritic cell to bead stimulations, dendritic cells were derived from 
human monocytes as previously described (10) with minor modifications. Briefly, 
PBMCs were allowed to adhere to plastic for 60 minutes at 37 °C in DC medium 
which consisted of X-Vivo 15 supplemented with 2 mM L-glutamine, 50 U/ml 
penicillin, 50 µg/ml streptomycin and 20 µg/ml gentamycin (all BioWhittaker). Non-
adherent cells were removed by washing, centrifuged and resuspended at 1 × 107 
cells/ml in T cell medium which consisted of RPMI 1640 containing 25 mM HEPES 
(Gibco/Invitrogen, Karlsruhe, Germany) supplemented with 10 % heat inactivated 
human AB serum (CC pro, Neustadt/W., Germany), 2 mM L-glutamine, 50 U/mL 
penicillin, 50 µg/mL streptomycin and 20 µg/ml gentamycin (all BioWhittaker). 10 
U/ml human IL-2 and 2.5 ng/ml human IL-7 (both R&D Systems, Wiesbaden, 
Germany) were added to non-adherent cells which were kept at 37 °C for up to 9 
days. Adherent cells were given DC medium containing 100 ng/ml human GM-
CSF (Leukomax; Novartis Pharma GmbH, Nuremberg, Germany) plus 40 ng/ml 
human IL-4 (R&D) and differentiated into immature dendritic cells at 37 °C. At day 
3, fresh DC medium containing IL-4 and GM-CSF was added. At day 6, cells were 
matured by adding fresh DC medium containing 10 ng/ml human TNF-α (R&D) 
and 1 µg/ml human prostaglandin E2 (Sigma). Cells that had lost adhesion were 
collected at day 9, irradiated with 33 Gy using a 1000 Elite gammacell (MDS 
Nordion, Ottawa, Canada) and used as professional APCs. Mature DCs were 
mostly CD14- CD40+ CD80+ CD83+ CD86+ and expressed high levels of HLA-DR 
(data not shown). For restimulations after priming with dendritic cells, 
cryopreserved autologous PBMCs were thawed, washed, irradiated as described 
above and used as non-professional APCs.  
Peptide loading was performed at 37 °C in X-Vivo 15 medium containing indicated 
concentrations of peptide for approx. 2 hours.  APCs were washed 5 times and 
resuspended in T cell medium. Coated microspheres stored at 4 °C were washed 
2 times in T cell medium.  
In vitro stimulations were initiated in 24 well plates with 5 × 106 responder cells 
plus 1 x 106 APCs or microspheres per well in 1.5 ml T cell medium. If not stated 
otherwise, 5 ng/ml human IL-12 p70 (R&D) was added with APCs or 
microspheres. After 3-4 days coincubation at 37 °C, fresh medium and 20 U/ml 
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human IL-2 (R&D) was added and cells were further incubated at 37 °C for 3-4 
days. This stimulation cycle was repeated twice. 
Sorted cells were cultured in 24 well plates in the presence of 5 × 105 cells/ml 33 
Gy irradiated fresh allogenic PBMCs, 5 × 104 cells/ml 210 Gy irradiated fresh LG2-
EBV cells, 150 U/ml IL-2 and 0.5 µg/ml PHA-L (Roche Diagnostics, Mannheim, 
Germany).  Cells were further expanded in T-cell medium containg 150 U/ml IL-2. 
 
Cell surface / intracellular cytometric analysis 
For tetrameric analyses, cells were washed in PBS/BSA/EDTA containing 10 
mg/ml sodium azide (Merck, Darmstadt, Germany) and stained at 4 °C for 20 
minutes in the same buffer containing Abs CD4-FITC and CD8-PerCP clone SK1 
(both from Becton Dickinson). After microsphere stimulation experiments, 100 
µg/ml unlabeled streptavidine (Sigma) was included. Cells were washed in PBS 
containing 2 % heat-incactivated FCS (PAN Biotech, Aidenbach, Germany), 2 mM 
sodium EDTA and 10 mg/ml sodium azide and tetramer stained at 4 °C for 30 
minutes in PBS/FCS/EDTA/Azide but including 50 % FCS. Tetramer reagents 
were always used at MHC concenctrations of 5 µg/ml. Stained cells were washed 
extensively in PBS/FCS/EDTA/Azide and fixed with 1 % formaldehyde (Merck). 
Cells were analysed on a four-color FACSCalibur (Becton Dickinson). Total 
specific cell numbers per sample were calculated by adding a defined number of 
microspheres to each sample and counting specific cell numbers as well as 
microsphere numbers by FACS. Therefore, (total specific cell number) = (number 
of specific cells counted) x (number of microspheres added) / (number of 
microspheres counted). 
Peptide pulsing of stimulator cells for inctracellular cytometry was performed as 
described above. Approximately 1 × 105 effector and stimulator cells were cultured 
in 96 well plates in T cell medium. After 1-2 hours, GolgiStop (Becton Dickinson) 
was added and incubation was continued for 4-5 hours. Thereafter, cells were 
permeabilized and stained using the Cytofix/Cytoperm Plus kit and anti-CD4-FITC, 
anti-IFN-γ-PE, and anti-CD8-PerCP, according to the manufacturer’s 
recommendations (Becton Dickinson). Cytometric analysis was performed using a 
FACSCalibur cytometer. 
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FIGURE S1.  Surface coating and stability of microspheres. Beads were labeled in the 
presence of 10 nM A*02/YVDPVITSI (A), 10 nM CD28 Ab (B) or both (C). Untreated beads (dotted 
line), freshly coated beads (solid line) or beads coated four weeks before analysis (dahed line) 
were stained with Abs against human β2m (left panel) or mouse IgG + IgM (right panel).  
 
 
 
 
FIGURE S2.  IFN-γ expression of 
T cell lines generated by microsphere 
driven expansions. Enriched CD8 T cells of 
one A*02+ healthy donor were stimulated 3 
times with beads labeled in the presence of 
10 nM CD28 Ab plus 10 nM of A*02 
refolded with indicated antigens. After a 4-5 
hours restimulation of T cell lines with 5 µM 
irrelevant peptide (left panel) or cognate 
peptide (right panel) loaded on T2 cells, 
cells were labeled with Abs CD4-FITC, 
CD8-PerCP and IFN-γ-PE. Plots were 
gated on CD4- lymphocytes and numbers 
in each plot indicate the percentage of IFN-
γ high expressing cells among CD8+ CD4- 
lymphocytes. 
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MHC class I and II restricted antigens are usually recognized by CD8+ and CD4+ T 
cells, respectively. Using HLA multimer analysis, we report functional circulating 
CD4+ and CD8+ T cells both specific for the same cytomegalovirus peptide bound 
to HLA-A*0101 in a case of congenital infection. This finding will change our 
understanding of T cell responses induced by severe viral infections in newborns. 
. 
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T cells are key effectors and orchestrators of the adaptive immune system. Mature 
α/β T cells are usually divided into CD8+ CD4- versus CD8- CD4+ cells. T cells with 
a CD8+ CD4- phenotype are associated with the recognition of short (8-12 amino 
acids) peptides bound to MHC class I molecules, acting as cytotoxic T 
lymphocytes (CTLs). CD8- CD4+ T cells usually recognize longer (10-15 amino 
acids) peptides bound to MHC class II molecules and are viewed as T helper cells 
(TH). However, there have been indications that this may be an oversimplification. 
First, CD8+ CD4+ T cells have been described in humans1 as mature T cells 
containing MHC class I and II specificities. Second, CD8+ CD4- as well as double-
negative T cells specific for MHC class II have been described in CD4-/- mice2,3. 
Finally, there have been sporadic reports of CD8- CD4+ T cells with MHC class I 
restriction in mice and men4,5,6,7,8. These studies have been performed after long-
term in vitro stimulation, leaving open the question whether these cells occur in 
vivo. Here, using HLA class I multimers9, we show for the first time the 
simultaneous detection of circulating functional CD8+ CD4- and CD8- CD4+ α/β T 
cells specific for the same HLA class I restricted CMV epitope in a patient with 
acute congenital viral infection.  
The term infant (BW 3215 g, HLA-A1+ B7+ B58+) presented classical symptoms of 
congenital CMV infection immediately after birth. Virus was detected in blood, 
urine and CSF. Inherited immunodeficiency syndroms have been ruled out as well 
as co-infection with HIV. Gancyclovir (GCV) treatment was initiated on day 2 p.p. 
and finished on day 135 p.p. After cessation of GCV repeated episodes of CMV 
infection with chorioretinitis and pneumonia occured within the first year of life, 
while thrombopenia, hepatitis and encephalitis resolved. The child survived with 
severe eye and CNS damages remaining in a chronic CMV carrier status. 
We investigated the CMV specific CTL response of this patient at the age of 14 
months using HLA class I multimer analysis of in vitro peptide stimulated PBMCs 
(see Supplementary Methods online). After one stimulation, CD8+ lymphocytes 
binding to the A*0101 multimer loaded with the immunodominant peptide 
YSEHPTFTSQY from CMV pp65 363-373 (A1/CMV) could be detected among 
patient PBMCs (data not shown). Immune responses to two immunodominant 
B*0702 restricted CMV peptides were not detectable in the patient. Surprisingly, 
we found also a CD8- population binding to A1/CMV after one stimulation. This 
finding was reobserved after a second stimulation (Fig. 1a). In parallel stimulations 
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with a negative control peptide, we observed no expansion of CD8+ or CD8- 
A1/CMV+ cells (data not shown). We then investigated the phenotype of A1/CMV 
binding CD8- and CD8+ cells (Fig. 1b and Supplementary Methods online). 
Binding of HLA multimers was peptide specific, since A1/CMV+ cells were not 
costained by an HIV-1 peptide-A*0101 multimer. Therefore, it is unlikely that 
multimer binding occurred via natural killer cell receptors. A1/CMV+ CD8+ and 
CD8- cells were mostly CD3+ CD56- TCRα/β+ TCRγ/δ− but differed in their CD4 
expression. A1/CMV+ CD8+ cells contained a minor subpopulation that 
coexpressed CD4, whereas all A1/CMV+ CD8- cells were CD4+. These data 
indicate that CD8+ and CD8- A1/CMV+ cells appear phenotypically as bona fide 
CD8+ and CD4+ α/β T cells, respectively.  
 
 
 
FIGURE 1 Phenotype and frequencies of HLA-A*0101 restricted CMV specific T cells. (a) 
HLA class I multimeric analysis of 2 x peptide stimulated PBMCs from negative control HLA-A1- 
CMV+ donor HD1, positive control HLA-A1+ CMV+ donor HD22 and HLA-A1+ CMV+ patient (Pt).  
Numbers represent percentages of A1/CMV+ cells among lymphocytes. (b) Phenotype of A1/CMV+ 
CD8+ (green) or CD8- (magenta) cells among lymphocytes from positive control donor HD22 and 
patient after 2 peptide stimulations. (c) Ex vivo detection of A1/HIV+ or A1/CMV+ CD8+ CD4- (upper 
half) or CD8- CD4+ (lower half) lymphocytes from negative control HLA-A1+ CMV- donor HD172, 
positive control HLA-A1+ CMV+ donors HD179, HD188, HD189, and HLA-A1+ CMV+ patient. Bars 
and error bars represent number and estimated standard error of multimer+ among 100,000 CD8+ 
CD4- or CD8- CD4+ lymphocytes. *The frequency of patient A1/CMV+ CD8- CD4+ cells was 
significantly higher compared to each control donor or to A1/HIV+ CD8- CD4+ frequencies in all 
donors (P<0.01, two-sided  Fisher's exact test).  
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FIGURE 2 Functional properties of A1/CMV+ CD8+ and CD8- cells. (a) Effector cells were 
stimulated at 37 °C for 6 h with the HLA-A1+ B-cell line COX loaded with an A*01 restricted peptide 
from HIV-1 or CMV. % IFN-γ cells among indicated populations were determined by intracellular 
cytokine staining and normalized to the frequencies of the indicated cell populations determined by 
multimer staining. (b) Effector cells were stimulated at 37 °C for 4 h with the allogeneic 51Cr labeled 
HLA-A1+ B-cell line COX loaded with an A*01 restricted peptide from HIV-1 or CMV at 37 °C for 6 
h. E:T ratios were normalized to the frequencies of the indicated cell populations determined by 
multimer staining.  
 
 
To investigate the expression of the TH1/TC1 cytokine IFN-γ and the cytotoxic 
capacity of A1/CMV specific subpopulations, we derived T-cell lines by HLA 
multimer-guided FACS sorting from stimulated patient PBMCs and expansion with 
irradiated allogeneic feeder cells, PHA, and IL-2.  All CD4+ T-cell lines were more 
than 99.9 % free of A1/CMV+ CD8+ cells and vice versa (data not shown and 
Supplementary Methods online). T-cell lines were rechallenged with A1+ cells 
loaded with HIV or CMV peptide and expression of IFN-γ was determined (Fig. 2a 
and Supplementary Methods online). The majority of A1/CMV+ CD4+ and a 
subpopulation of multimer binding CD8+ cells specifically expressed IFN-γ under 
these conditions. TNF-α yielded similar results (data not shown). In a parallel 51Cr 
release experiment, both CD8+ and CD4+ cells displayed specific cytotoxicity 
against A1+ allogeneic cells pulsed with peptide (Fig. 2b and Supplementary 
Methods online). However, lysis was about 50 x higher in CD8+ compared to 
CD4+ cells. Peptide pulsed A1- cells were invariably not killed and A1/CMV- CD8+ 
or CD4+ T-cell lines from the patient displayed no specific cytotoxicity against the 
CMV peptide (data not shown). 
One may argue that CD4+ A1/CMV+ cells reported here are an in vitro artefact, 
e.g. due to a changed coreceptor expression after prolonged cell culture. To be 
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able to detect circulating A1/CMV specific T cells ex vivo, we used modified HLA 
class I multimers with reduced background binding10 (Fig. 1c and Supplementary 
Methods online). These frequency counts indicate that among patient PBMCs, 
A1/CMV+ CD8+ CD4- and CD8- CD4+ were present.  
The occurrence of CD4+ T cells specific for CMV has been demonstrated in 
congenital CMV infection but without analysing their HLA restriction11. Our data 
support the hypothesis that the repertoire of circulating CD4+ CD8- α/β T cells 
does also contain HLA class I restricted cells. For the first time, the presence of 
such cells could be shown directly ex vivo. CD8- HLA class I multimer+ cells have 
been described previously12 but were found to bind multimers in a non-HLA 
restricted, non-peptide dependent manner. In contrast, CD8- cells shown here do 
bind HLA dependent of peptide and their specificity was further confirmed by 
functional assays. Within the same patient, cells of CD8+ CD4- phenotype were 
found for the identical CMV epitope and HLA restriction. This observation goes 
along with the lack of T cells specific for immunodominant B*0702 epitopes. As 
this patient suffers from CMV infection, it remains unclear whether the found cells 
play a beneficial role for the control of the disease, as has been suggested 
previously in mice5. Functionally, CMV specific CD4+ and CD8+ cells were 
consistent with conventional TH1 and CTLs, respectively. This study demonstrates 
that HLA class I restricted CD4+ and CD8+ cells can be detected and discriminated 
using HLA multimers. Furthermore, it highlights the importance not to overlook 
CD4+ cells in monitoring vaccines which are aimed at  HLA class I restricted 
immune responses. Determining the in vivo function of HLA class I restricted, 
CD4+ T cells will be a challenge for the future 
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Supplementary material for Walter S et al: HLA class I restricted CD4+ T cells 
in congenital viral infection 
 
Cells, Peptides and MHC multimers. PBMCs were prepared from heparinized 
patient blood or HLA typed fresh buffy coats provided by the blood bank, 
University of Tübingen. PBMCs were isolated using standard gradient separation 
techniques and cryopreserved until use. Informed consent was obtained from the 
parents for all investigations. COX (HLA-A1+, ECACC # 85102902), LCL721.45 
(HLA-A1-, as described previously1) and LG2-EBV (a kind gift of of P. van der 
Bruggen, Brussels) are human B-lymphoblastoid cell lines. Peptides for MHC 
refoldings and cellular assays were synthesized using standard Fmoc-chemistry. 
Peptides in this study were A*0101 restricted YSEHPTFTSQY and B*0702 
restricted RPHERNGFTVL, and TPRVTGGGAM from HCMV pp65 363-3732, 265-
2753 and 417-4264, respectively. As negative controls, A*0101 restricted peptide 
GSEELRSLY from HIV-1 gag p17 70-786 and B*0702 restricted APRTVALTA from 
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HLA-DPB1*0101 9-175 were used. Biotinylated recombinant HLA-A*0101 
molecules were prepared analogous to HLA-A*0201 molecules described 
previously 7,8. Biotinylated recombinant HLA-A*0101 molecules with reduced 
background binding were generated by introducing the point mutation A245V in 
the α3 domain as has been described9. Fluorescent multimers were generated by 
coincubating biotinylated HLA molecules with streptavidin-PE or -APC (Molecular 
Probes, Leiden, The Nederlands) at a 4:1 molar ratio 
 
Multimer analysis of stimulated PBMCs.  Thawed PBMCs were 
washed and cultured overnight in T-cell medium, which consisted of RPMI 1640 
containing 25 mM HEPES (Gibco/Invitrogen, Karlsruhe, Germany) supplemented 
with 10 % heat inactivated human AB serum (CC pro, Neustadt/W., Germany), 2 
mM L-glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin and 20 µg/ml 
gentamycin (all Cambrex Bio Science, Verviers, Belgium). 5 µg/ml of each CMV 
peptide YSEHPTFTSQY, RPHERNGFTVL and TPRVTGGGAM was added to the 
stimulation sample. Negative control sample was supplemented with 5 µg/ml 
peptide APRTVALTA. Cells were given fresh medium plus 20 U/ml recombinant 
human IL-2 (Chiron, Emeryville, California/USA) 3-4 days later and incubation was 
continued for 3-4 days. This protocol was repeated weekly for a maximum number 
of three stimulations. For multimer staining, an aliquot of cells was removed 7 days 
after the last stimulation, washed and resuspended in buffer consisting of PBS 
(Cambrex) supplemented with 0.5 % protease-free BSA, 2 mM sodium EDTA 
(both Sigma, Taufkirchen, Germany) and 10 mg/ml sodium azide (Merck, 
Darmstadt, Germany). When indicated, cells were incubated with mouse anti 
human CD3 antibody OKT3 (a kind gift of Gundram Jung, Tübingen), washed and 
stained with FITC labeled goat anti mouse F(ab')2 fragments (Jackson 
ImmunoResearch Laboratories, West Grove, Pennsylvania/USA). After blocking 
with 10 % heat inactivated mouse serum (CC pro), cells were washed and stained 
with labeled antibodies as indicated, which were CD8-PerCP clone SK1, TCRα/β-
FITC clone WT31, TCRγ/δ-PE (all Becton Dickinson, Heidelberg, Germany), CD4-
FITC and CD56-PE (all Coulter Immunotech, Marseille, France). Cells were 
washed in PBS containing 2 % heat-incactivated FCS (PAN Biotech, Aidenbach, 
Germany), 2 mM sodium EDTA and 10 mg/ml sodium azide and multimer stained 
at 4 °C for 30 minutes in the same buffer but including 50 % FCS. Multimer 
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reagents were always used at MHC concenctrations of 5 µg/ml. Washed cells 
were fixed in PBS/FCS/EDTA/Azide containing 1 % formaldehyde (Merck) and 
cytometry was performed on a four colour FacsCalibur cytometer (Becton 
Dickinson).  
 
Sorted T cell lines. For sorting, cells were stained as above under aseptic 
conditions using Abs CD8-APC (clone SK1, Becton Dickinson), CD4-FITC 
(Immunotech), and multimer-PE. Sorting of A1/CMV+/- CD8+/- CD4+/- cells as 
indicated was performed on a FacsVantage (Becton Dickinson) and sorted cells 
were cultured in 24 well plates in T-cell medium in the presence of 5 × 105 cells/ml 
33 Gy irradiated fresh allogeneic PBMCs, 5 × 104 cells/ml 210 Gy irradiated fresh 
LG2-EBV cells, 150 U/ml IL-2 and 0.5 µg/ml PHA-L (Roche Diagnostics, 
Mannheim, Germany). Cells were further expanded in T-cell medium containg 150 
U/ml IL-2. 
 
Intracellular cytokine staining. Approximately 1 x 105 stimulator cells COX per 
condititon were incubated in X-Vivo 15 medium (Cambrex) supplemented with 5 
µg/ml indicated peptide at 37 °C for 2 hours. Cells were resuspended in T-cell 
medium with effector T cells as indicated at an approximate effector to target ratio 
of 1:1. After one hour, GolgiStop (Becton Dickinson) was added and incubation 
was continued for 5 hours at 37 °C. Cells were permeabilized and stained using 
the Cytofix/Cytoperm Plus kit and Abs CD4-PerCP, CD8-APC, IFN-γ-FITC and 
TNF-α-PE according to the manufacturer’s recommendations (Becton Dickinson). 
Analysis was performed using a FACSCalibur cytometer. % IFN-γ expressing cells 
among indicated populations was calculated from IFN-γ intracellular and MHC 
multimer staining experiments as follows:  (% IFN-γ expressing cells among 
lymphocytes of indicated CD8/CD4 phenotype) / (% indicated multimer+/- 
population among lymphocytes of indicated CD8/CD4 phenotype) x 100. 
 
Cytotoxicity assay.  Target cells COX or LCL721.45 were loaded with 10 
µg/ml peptide at 37°C for 90 minutes. Cytotoxicity was then tested in a standard 4 
h 51Cr release assay using 3000 target cells per well. % specific lysis was 
calculated as follows: (experimental release - spontaneous release) / (detergent 
release - spontaneous release) x 100. Indicated were specific effector to target 
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ratios determined as follows: (ratio of microscopically counted effector per target 
cells from 51Cr release experiment) * (% indicated population among lymphocytes 
from multimer staining experiment) / 100. 
 
Ex vivo multimer analysis. Thawed PBMCs were washed and resuspended 
in PBS/FCS/EDTA/Azide. Cells were then incubated with Abs CD4-FITC 
(Immunotools, Friesoythe, Germany) and CD8 PerCP for 20 minutes at 4 °C. Cells 
were washed and resuspended in PBS/FCS/EDTA/Azide containing 50 % FCS 
and stained with point mutated multimers HLA-A*0101 A245V loaded with 
peptides YSEHPTFTSQY (PE) and GSEELRSLY (APC) at MHC concentrations of 
5 µg/ml per multimer for 30 minutes at 4 °C. Washed cells were fixed as above 
and analyzed on a FacsCalibur cytometer. Proportion p of multimer binding cells 
among n lymphocytes of indicated CD8/CD4 phenotype was determined. Number 
of multimer binding cells among 100,000 lymphocytes of indicated CD8/CD4 
phenotype was calculated as (p*100,000) and estimated standard error of this 
number was calculated as follows:100,000 x (p x (1 - p) / n )1/2 
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Combining cell surface phenotyping with functional analysis, human CD8+ T cells 
have been divided into several subsets which are being studied extensively in 
diverse physiological situations, such as viral infection, cancer and ageing. In 
particular, so-called terminally-differentiated effector cells possess a 
CD45RA+CCR7-CD27-CD28- phenotype, contain perforin and in different models 
have been shown to exert direct ex vivo killing and to release interleukins upon 
both antigen nonspecific or specific stimulation. Using HLA-class I multimers, we 
have identified a high frequency of peripheral CD8+ T cells which recognize a 
peptide derived from the self-protein cytokeratin 18 presented by the HLA-A*0201 
molecule. These cells can be detected in approximately 15% of the HLA-A2-
positive healthy donors tested. A detailed analysis revealed that they must have 
divided extensively in vivo, have an effector cell phenotype and express various 
natural killer cell inhibitory receptors. Interestingly, however, they remained 
unresponsive to antigen-specific stimulation in vitro, in terms of cytotoxicity and 
cytokine secretion. Thus, cytokeratin 18-specific cells constitute a frequently 
encountered, new CD8+ T lymphocyte subpopulation without classical effector 
status and so far with unknown function. 
 
. 
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Introduction 
 
Many recent studies have investigated the heterogeneity of human CD8+ 
peripheral T lymphocytes. The description of subpopulations and stages of 
differentiation is mainly based on the expression pattern of various cell-surface 
receptors and on functional properties such as proliferation, cytokine secretion or 
cytotoxicity. Thus, CD45RA/RO and CD27 were at first used to distinguish naïve 
cells (CD45RA+CD27+) from memory cells (CD45RA-CD27+), which both lack 
immediate cytolytic function, and effector cells (CD45RA+CD27-), with high ex vivo 
cytotoxic potential 1. CD8+ subpopulations can also be defined using the 
costimulatory receptor CD28, with CD8+CD28- cells preferentially exerting ex vivo 
redirected cytotoxicity (which correlates with intracellular perforin expression) and 
representing an in vivo expanded population with short telomeres 1-3. More 
recently, differential expression of the lymph node homing receptor CCR7 was 
used to subdivide CD8+ T cells into four subpopulations: naïve (CD45RA+CCR7+), 
central memory (CD45RA-CCR7+), effector memory (CD45RA-CCR7-), and 
effectors, or terminally-differentiated effector cells (CD45RA+CCR7-). Each of 
these subsets presents different functional properties, in terms of in vitro 
proliferative capacity in response to TCR-mediated signals or interleukins, 
cytotoxic potential and interleukin secretion 4,5. Combining the expression of the 
latter antigens with expression of the costimulatory receptors CD27 and CD28 
allowed the identification of additional subsets with properties of both naïve and 
effector T cells 6. A growing number of markers, such as CD57 7, 
inhibitory/activatory natural killer cell receptors 8-10, or interleukin and chemokine 
receptors 11,12, is now available to refine further the definition of human functional 
CD8+ T-cell subpopulations. 
Taking advantage of tetramer technology, antigen-specific T cells are now being 
studied in different situations such as viral infections, ageing and cancer. Analysis 
of CD8+ T lymphocytes specific for HLA-class I epitopes from persistent viruses 
such as HIV, EBV and HCMV has showed that their distribution in the 
naïve/memory/effector compartments, as defined with the surface markers 
described above, differs for these different viruses 13,14. On the functional level, 
and following the observations made with antigen-nonspecific populations, effector 
and effector memory virus-specific cells, in contrast to naïve or central memory 
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cells, possessed poor proliferative capacity but high antigen-specific cytotoxicity 
13,15. However, some studies show that terminally-differentiated effector CD8+ 
cells, CD45RA+/CD27-/CD28-/CCR7- can, at least under certain conditions, 
proliferate vigorously 12,16, whereas CCR7+ cells can exert immediate effector 
functions 17. It was also observed that effectors can revert to a central memory, 
CD45RA-CCR7+ phenotype, while maintaining effector functions 18. All these and 
other reports suggest that the CD8+ subpopulations are intimately linked, or form a 
continuum, and indeed their lineage relationships are currently debated 13,14,19. 
Further dissection of antigen-specific, CD8+ functional subsets is certainly a crucial 
step for the understanding of the CD8 lineage differentiation process and 
eventually its manipulation for therapeutic purposes. Because the detectable 
frequency of peripheral tumor antigen-specific CD8+ T cells is generally extremely 
low in cancer patients, few studies have been so far able to analyse 
simultaneously phenotype and function of such CD8+ lymphocytes ex vivo. The 
best studied examples are HLA-A*0201-restricted, Melan-A-specific cells. In the 
blood of healthy donors, these cells are present at a surprisingly high frequency 
and possess a naïve phenotype (CD45RA+CCR7+), whereas they are CD45RA-
CD45RO+CCR7- and show direct ex vivo activity (cytotoxicity and IFN-γ 
production) in a significant proportion of melanoma patients 20-22. 
 We have recently identified by mass spectrometry a nonameric oligopeptide 
derived from the cytokeratin 18 protein (CK18 365-373) as a natural HLA-A2 
ligand found on primary renal cell carcinomas. Using HLA-A*0201 multimers 
refolded with this peptide, we detected A2/Ker-binding CD8+ T cells at relatively 
high frequencies in some healthy donor PBMC 23. We now report on the 
phenotypic and functional characterisation of this particular CD8+ subpopulation. In 
contrast to Melan-A-specific CD8+ T cells found in healthy donors, the A2/Ker-
binding cells have a phenotype previously associated with terminally-differentiated 
effector cells capable of immediate function. However, we were unable to detect 
production of IFN-γ or potent cytotoxic activity upon ex vivo peptide-specific 
stimulation. We propose that these “dysfunctional” CK18-specific cells represent a 
new subset or differentiation stage of T lymphocytes with unknown function(s), 
suggesting that CD8+ effector cells are functionally heterogeneous and might be 
further divided into distinct subsets. 
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Methods 
 
Cells and culture media 
Blood samples were obtained after informed consent from healthy volunteers or 
fresh buffy coats provided by the Blood Bank, University of Tübingen, and HLA-
typing was performed serologically. Peripheral mononuclear cells (PBMC) were 
isolated using a standard Ficoll gradient separation (Ficolite H, Linaris, Wertheim-
Bettingen, Germany) and used either immediately or cryopreserved in heat-
inactivated fetal calf serum (FCS, PAA Laboratories, Linz, Austria) containing 10% 
DMSO. T-cell culture medium consisted of RPMI 1640 containing 25 mM HEPES, 
2 mM L-glutamine (Invitrogen, Karlsruhe, Germany), supplemented with 10% heat-
inactivated human AB serum (CC pro, Neustadt/W., Germany), 50 U/mL penicillin, 
50 µg/mL streptomycin and 20 µg/mL gentamycin (Cambrex, Verviers, Belgium). 
The TAP-deficient cell line T2 (HLA-A2low) was maintained in culture in RPMI with 
2 mM L-glutamine, 50 U/mL penicillin, 50 μg/mL streptomycin and 10% FCS. 
 
Peptides and fluorescent multimers 
Peptides for HLA-class I multimers and functional assays were synthesized using 
standard Fmoc-chemistry, dissolved in bidistilled water containing 10% DMSO at 1 
mg/ml, aliquoted and stored at -80ºC before use. Purity was checked by reverse-
phase HPLC and was always > 80%. The cytokeratin 18 365-373-derived peptide 
ALLNIKVKL (Ker) has recently been described 23. Viral-derived peptides 
NLVPMVATV (CMV) from HCMV pp65 495-503, GILGFVFTL (Flu) from Influenza 
M1 58-66, LLDFVRFMGV (EBV1) from EBV EBNA-6 284-293, GLCTLVAML 
(EBV2) from EBV IE63 259-267, CLGGLLTMV (EBV3) from EBV LMP2 426-434, 
ILKEPVHGV (HIV) from HIV-1 RT 476-484, as well as YLLPAIVHI (p68) from 
human helicase p68 and ELAGIGILTV (Mel) as a modification of Melan/MART-1 
26-35 are all well-documented HLA-A*0201 epitopes or ligands 
(www.syfpeithi.de). Abbreviations given in brackets were used to identify peptides 
throughout the text. 
Biotinylated recombinant HLA-A*0201-peptide monomers were produced 
essentially as previously described 24. Fluorescent multimers were generated by 
coincubating biotinylated HLA-peptide monomers with streptavidin-PE or 
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streptavidin-APC (Molecular Probes, Leiden, The Netherlands) at a 4:1 molar 
ratio. 
 
Multimer staining and phenotypic analysis 
Staining of cells with multimers and fluorochrome-labeled monoclonal antibodies 
(mAb) was performed as follows: PBMC were thawed in FACS buffer (PBS 2% 
FCS, 2 mM EDTA and 0.02% NaN3), washed and generally 1 x 106 cells were 
stained for 20 min with anti-CD8PerCP (clone SK1, Becton Dickinson, Heidelberg, 
Germany) plus either mAb CD19FITC, CD11aFITC, CD45RAFITC, TCR α/βFITC 
(all Becton Dickinson), CD27FITC, CD28FITC, CD45ROFITC, CD57FITC, or 
CD62LFITC (all Coulter-Immunotech, Hamburg, Germany). After washing, cells 
were labeled with diluted multimers at 4°C for 30 min (HLA concentration 5 µg/mL) 
in FACS buffer containing 50% FCS. For Figure 1A, cells were stained as 
previously reported, using multimers and mAb CD8PerCP plus CD4FITC 23. 
For staining of the surface marker CCR7, PBMC were labeled first with the rat 
hybridoma supernatant 3D12 (kindly provided by R. Förster, Hannover, Germany), 
washed and incubated with FITC- or PE-labeled donkey anti-rat F(ab')2 fragments 
(Jackson ImmunoResearch Laboratories, West Grove, PA). After blocking with 
10% heat-inactivated mouse serum (CC pro) for 10 min, cells were washed and 
stained with fluorochrome-labeled mAb and multimers as detailed above. 
For staining of the inhibitory killer cell lectin-like receptor G1 (KLRG1), cells were 
first incubated with Polyglobin 2.5% (Bayer, Leverkusen, Germany) then with the 
mouse hybridoma supernant 13A2 (kindly provided by H. Pircher, Freiburg, 
Germany) which was visualised using a rabbit anti-mouse F(ab´)2-FITC antibody 
(Jackson). Blocking and further incubation steps were performed as above. Other 
mAb CD94/NKG2A, KIR2DL1, KIR2DL2 and ILT2 (kindly provided by A. Moretta, 
Genova, Italy) were labeled using a goat anti-mouse-FITC polyclonal 
(DakoCytomation, Untermüli, Switzerland) and blocking was performed with 
mouse IgG1 and IgG2a isotype matched mAb (Coulter-Immunotech) followed by 
multimers A2/Ker-PE plus A2/CMV-APC staining and finally incubation with 
CD8APC-Cy7 (SK1). 
Analysis of perforin expression was done by staining the cells with mAb 
CD8PerCP and multimers first, fixing and permeabilizing them with 
Cytofix/Cytoperm and incubating with a FITC-coupled mAb directed against 
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perforin (Becton Dickinson) in permeabilizing buffer PBS containing 0.5% BSA, 0.1 
% Saponin and 0.02% NaN3. 
All samples were fixed in FACS buffer containing 1% formaldehyde and three or 
four-color analysis was performed on FACSCalibur or FACSVantage cytometers 
equipped with the CellQuest Pro software (Becton Dickinson). 
 
Cytokine production 
Intracellular cytokine stainings were performed using a standard procedure: briefly, 
1-2 x 106 total PBMC per condition were stimulated in 200 µL T-cell culture 
medium in the presence of GolgiStop (Becton Dickinson), 5 µg/mL of various 
synthetic peptides for 13 h or 50 ng/mL phorbol myristate acetate (PMA) together 
with 1 μM Ca2+ ionophore ionomycin (both Sigma-Aldrich, Taufkirchen, Germany) 
for 2 h at 37°C and 5% CO2. Cells were then washed and stained with CD8PerCP 
and multimers, followed by a permeabilization step with Cytofix/Cytoperm and 
staining for intracellular cytokine production using an anti-IFN-γFITC mAb (Becton 
Dickinson) diluted in permeabilizing buffer. After the last incubation step, cells 
were washed and analyzed by FACS. 
Analysis of IFN-γ mRNA production by quantitative real-time PCR was performed 
essentially as described 25. Briefly, thawed PBMC were plated at 1 x 106 cells per 
condition in 500 µl medium and allow to recover overnight at 37°C. Synthetic 
peptides were then added at 5 µg/mL for 3 h before RNA extraction using Trizol 
(Invitrogen Lifetechnologies, Karlsruhe, Germany). cDNA was synthetised using 
random hexamer primers (Amersham Biosciences, Freiburg, Germany) and M-
MLV reverse transcriptase (Promega GmbH, Mannheim, Germany) in the 
presence of 10 U RNasin (Roche Diagnostics, Mannheim, Germany). Real-time 
PCR was run on an ABI Prism 7000 Sequence Detection System (Applied 
Biosystems, Darmstadt, Germany) in duplicates for IFN-γ mRNA and CD8 mRNA, 
using Taqman PCR master mix (Applied Biosystems), specific primers and 
fluorescent probes. Data analysis was performed as reported previously using the 
delta cycle threshold method (ΔCT) 23. 
 
Cell sorting for cytolytic assay and TREC analysis 
Cryopreserved PBMC were thawed, washed and allowed to recover by overnight 
incubation. CD8+ T cells were magnetically enriched by negative selection using a 
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CD8 T-cell isolation kit (Miltenyi Biotec, Bergisch Gladbach, Germany) according 
to the manufacturer's instructions. Enrichment was always > 80%. 
For the cytolytic assays, CD8+ cells were stained with multimers A2/Ker-PE and 
A2/CMV-APC for 25 min at 4°C. CD8FITC mAb (clone SK1) was then added for 
20 additional min at 4°C. After washing, multimer-positive or negative cells were 
sorted on a FACSVantage, and incubated overnight in T-cell medium. T2 cells 
were preloaded with 5 μg peptide for 1 h and labeled with 100 μCi Na251CrO4 
(Hartmann Analytic, Braunschweig, Germany). 1000 T2/well were used at different 
effector to target ratios in a standard 6 h 51Cr release assay. Spontaneous (T2 in 
medium alone) and maximal (T2 in 1% Triton X100) chromium release was 
determined and % specific lysis was calculated as follows: (cpm experimental 
release – cpm spontaneous release) / (cpm total release – cpm spontaneous 
release) × 100. 
For the T-cell receptor excision circle (TREC) analysis, CD8+ MACS-enriched cells 
were stained as described above with multimer A2/Ker-PE and CD8APC-Cy7 
(SK1). In parallel, a fraction of these CD8+ cells was stained with anti-CCR7 3D12 
antibody, goat anti-rat-APC (Becton-Dickinson) and mAb CD8APC-Cy7 and 
CD45RA-ECD (Immunotech). Naïve (CD45RA+CCR7+), effector (CD45RA+CCR7-) 
and CK18-specific CD8+ populations were then sorted on a FACSVantage. DNA 
was extracted and analysis of TREC content was performed in duplicate by 
quantitative real-time PCR using specific primers. CT values differed by less than 
0.35 between replicates. Quantification was achieved using serial dilutions of a 
standard plasmid containing the TREC sequence 26.  
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Results 
 
HLA A*0201/Ker-binding CD8+ T cells are frequently detected in healthy 
donor PBMC 
We have recently described a subpopulation of human peripheral CD8+ T cells 
present in some healthy individuals and binding specifically to HLA-A*0201 
multimers folded with one peptide derived from the normal self-protein cytokeratin 
18 (A2/Ker) 23. To further characterize this population, we have now tested 33 
HLA-A2+ donors, 5 of whom possessed cells binding to the A2/Ker multimers with 
a frequency ranging from 0.05% (HD93) to 0.55% (HD7) of the total CD8+ cell 
population. Staining intensity varied between donors, as examplified in Figure 1 by 
HD92 and HD93. In contrast, no specific staining was detectable in 20 HLA-A2- 
controls (Figure 1A and data not shown).  
 
 
 
Figure 1. Ex vivo detection of CK18-specific CD8+ T cells in healthy donors. (A) PBMC from 
HLA-A2+ (HD2, HD6, HD90, HD92, HD93) or HLA-A2- (HD91) healthy donors were stained with 
mAb CD8PerCP, CD4FITC and multimers A2/Ker-PE plus A2/CMV-APC. Cells are gated on CD4- 
lymphocytes. Numbers represent percentage of A2/Ker multimer positive cells among CD8+ 
lymphocytes. (B) PBMC from HLA-A2+ healthy donors HD7 and HD37 were stained with mAb 
CD8PerCP, CD19FITC plus multimers A2/Ker-PE, A2/CMV-APC and A2/Flu-APC. Cells are gated 
on CD19- (upper and middle panel) or CD19-CD8+ lymphocytes (lower panel). Numbers represent 
percentage of A2/Ker multimer positive cells among CD8+ lymphocytes. 
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As shown in Figure 1B for the two additional donors HD7 and HD37, A2/Ker-
binding CD8+ T cells were not concomitantly stained with a mix of two multimers 
specific for viral-derived epitopes, suggesting that the reactivity observed was 
specific for the CK18-peptide. A2/Ker binding was reproducible with 3 batches of 
separately synthesized peptides and multimers. Furthermore, HLA-A*0201/Ker 
multimers bearing the point mutation A245V that leads to reduced CD8 dependent 
binding also retained specific staining (data not shown). Finally, a stable frequency 
of A2/Ker-specific cells was detected in several donors at different times over 
more than one year. To summarize, we observed that CK18-specific, HLA-
A*0201-restricted CD8+ T-cell populations could be detected in about 15% of HLA-
A2+ healthy donors. Two of these, HD7 and HD37 (0.55% and 0.24% of the CD8+ 
T cells binding to A2/Ker, respectively) were selected for further characterisation. 
A2/Ker binding was reproducible with 3 batches of separately synthesized 
peptides and multimers. Furthermore, HLA-A*0201/Ker multimers bearing the 
point mutation A245V that leads to reduced CD8 dependent binding also retained 
specific staining (data not shown). Finally, a stable frequency of A2/Ker-specific 
cells was detected in several donors at different times over more than one year. 
To summarize, we observed that CK18-specific, HLA-A*0201-restricted CD8+ T-
cell populations could be detected in about 15% of HLA-A2+ healthy donors. Two 
of these, HD7 and HD37 (0.55% and 0.24% of the CD8+ T cells binding to A2/Ker, 
respectively) were selected for further characterisation. 
 
A2/Ker-binding CD8+ lymphocytes have a phenotype of antigen-experienced 
T cells 
With the notable exception of HLA-A*0201/Melan-A-specific cells, the frequencies 
of A2/Ker multimer-binding CD8+ cells are much higher than what has been 
estimated for single-epitope specific naïve T cells (< 1/100,000 CD8+ T cells) 20,27. 
A panel of surface markers associated with naïve or antigen-experienced 
lymphocytes was tested in combination with multimer staining in HD7 and HD37 
(Figure 2 and Table 1). CK18-specific cells expressed the tyrosine phosphatase 
isoform CD45RA, although at different levels (CD45RAdim for HD7 and CD45RAhigh 
for HD37), but mainly lacked the costimulatory receptor CD28 (Figure 2A). This is 
indicative of antigen-experienced, but not naïve CD8+ T cells.  
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Figure 2. CK18-specific CD8+ cells have a phenotype of antigen-experienced T lymphocytes. 
(A) PBMC from donors HD7 or HD37 were stained with mAb CD8PerCP and FITC labeled mAb 
against T-cell surface antigens CD45RA, CD27, CD28 or CD57, followed by multimer staining with 
A2/Ker-PE and A2/CMV-APC. Cells are gated on CD8+ lymphocytes. Data shown for the CD45RA 
staining were derived from a separate experiment. (B) PBMC from HLA-A2+ donors HD15, HD1, 
HD7 and HD37 were stained with CD8PerCP, CD45RAFITC, CCR7/donkey anti rat-PE, followed 
by multimer staining with A2/Mel-APC, A2/Flu-APC or A2/Ker-APC. Cells shown in grey are gated 
on CD8+ lymphocytes whereas highlighted cells shown in black represent multimer-positive CD8+ 
lymphocytes. HD37 staining was performed in a distinct experiment. 
 
Variable lack of expression of the costimulatory receptor CD27 and upregulation of 
the antigen CD57 further strengthened this observation. Recently, the expression 
of both CD45RA and the chemokine receptor CCR7 has been employed to 
differentiate between naïve (CD45RA+CCR7+), central memory (CD45RA-CCR7+), 
effector memory (CD45RA-CCR7-) and effector (CD45RA+CCR7-) CD8+ T cells. 
Whereas Melan-A-specific cells from HD15 and influenza-specific CD8+ cells from 
HD1 possessed a phenotype of naïve and effector memory cells, respectively, it 
was clear that A2/Ker-binding cells had a predominantly effector phenotype, i.e. 
CD45RA+CCR7- in HD7 and HD37 (Figure 2B), as well as in several other donors 
tested (data not shown). Other mAb were used to complement this 
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immunophenotyping and results are summarized in Table 1. CK18-specific cells 
were T-cell receptor (TCR)-α/β-positive T cells expressing high levels of CD11a 
and intracellular perforin, but low levels of CD62L. Their phenotype was clearly 
different from that of Melan-A-, influenza- or CMV-specific cells from the same 
donors. Interestingly, they were not identical in the two donors tested, as judged 
by the variable expression of CD45RA, CD27 and CD57. 
 
 
Table 1. Phenotype of peripheral A2/Mel, A2/Flu, A2/CMV and A2/Ker binding 
CD8+ T cells in several healthy donors 
 
 Donors and HLA multimers  
 HD15 
A2/Mel 
HD1 
A2/Flu 
HD7 
A2/CMV 
HD37 
A2/CMV 
HD7 
A2/Ker 
HD37 
A2/Ker 
TCRα/β+  100  100  100  100  100  100 
CD45RA+  96  6  38  54  59  83 
CCR7+  94  8  3  3  4  4 
CD11ahi  21  94  99  99  98  98 
CD27+  99  94  55  29  14  50 
CD28+  93  94  21  11  11  10 
CD45RO+  18  88  56  n.t.  40  n.t. 
CD57+  2  10  68  71  89  36 
CD62L+  52  9  5  n.t.  6  n.t. 
Perforin+  8  8  73  88  91  76 
 
Numbers represent percentage of surface or intracellular antigen expressing cells among HLA 
multimer+ CD8+ lymphocytes. Data presented derived from separate experiments and are 
representative of at least two independent stainings for each population. 
n.t. not tested 
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To confirm that CK18-specific cells are effector cells which had previously 
encountered antigen in vivo, we performed a quantitative analysis of T-cell 
receptor excision circle (TREC) levels within populations of sorted cells. As TREC 
are a non-replicative byproduct of the T-cell receptor rearrangement and are 
diluted upon cell divisions, a low TREC level is indicative of a large number of cell 
divisions in the T cell's past 26. Results obtained for donor HD7 are shown in 
Figure 3 and demonstrate that A2/Ker-binding sorted cells carry very small 
amounts of TREC, equivalent to autologous CD45RA+CCR7- effectors but much 
less than autologous CD45RA+CCR7+ naïve cells. 
In conclusion, these data show that cytokeratin 18-specific CD8+ T cells have a 
phenotype and a replicative history which has been described before for so-called 
"terminally-differentiated effector cells", at least in the two donors tested. 
 
 
 
 
 
Figure 3. CK18-specific CD8+ cells contain low levels of TREC. PBMC from HD7 were sorted 
into naïve (CD45RA+CCR7+), effector (CD45RA+CCR7-) and A2/Ker binding CD8+ T cells. TREC 
levels were determined by quantitative real-time PCR and normalized for 100 cells of each 
subpopulation. Bars represent mean of TREC values obtained for two consecutive cell sortings of 
each CD8+ T lymphocyte subset. DNA extraction and duplicate real time PCR amplification were 
performed in parallel. One of two representative experiments performed with two PBMC samples 
obtained at different time points is shown. 
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Figure 4. CK18-specific CD8+ cells do not produce IFN-γ upon peptide stimulation. (A) PBMC 
from donor HD7 were stimulated for 3 h with peptides HIV, p68, CMV, a viral-derived epitope mix 
(antigens CMV, Flu, EBV1, EBV2 and EBV3) or the peptide Ker. Duplicate results are expressed 
for each stimulation in fold increase IFN-γ mRNA copy numbers normalized to CD8 mRNA, relative 
to the same ratio obtained with the control stimulation, i.e. PBMC cultivated in the presence of the 
HIV peptide, which is set to 1. (B) PBMC from the same donor were stimulated as described in the 
methods section with either the CMV or the Ker peptides for 13 h. (C) PBMC from donors HD7 and 
HD37 were incubated for 2 h without stimulus or with a combination of PMA and ionomycin. After 
stimulation, cells were stained with CD8PerCP, IFNγFITC and multimers A2/Ker-PE and A2/CMV-
APC. Dot plots are gated on CD8+ lymphocytes. 
 
CK18-specific CD8+ T cells are dysfunctional in terms of cytokine production 
and specific killing 
Terminally-differentiated effector CD8+ T cells have been reported to display 
immediate cytotoxicity and rapid production of cytokines such as IFN-γ after 
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stimulation. We therefore evaluated the functionality of A2/Ker specific cells. 
However, no IFN-γ production upon specific CK18 peptide stimulation was 
detectable, neither at the transcriptional (i.e. production of specific mRNA, Figure 
4A) nor protein (Figure 4B) levels. As expected, autologous virus-specific, 
especially CMV-specific, HLA-A*0201-restricted T cells responded to specific 
peptide stimulation in the same assays, upregulating mRNA and for the majority of 
them, producing IFN-γ as shown in Figure 4B. Additionally, we observed that the 
intensity of the CMV-multimer staining decreases notably after contact with the 
CMV peptide (Figure 4B, lower panel), most probably reflecting the internalization 
of the TCR (which is known to occur following activation of T cells). In contrast, no 
obvious TCR downregulation was observed for A2/Ker-stained cells after CMV or 
Ker peptide stimulation. The absence of IFN-γ, as well as  TNF-α, production in the 
presence of the Ker peptide was also observed for donor HD37 (data not shown). 
To test whether CK18-specific cells completely lack the ability to synthesize IFN-γ, 
we stimulated PBMC from donors HD7 and HD37 with the TCR-independent T-cell 
activator, PMA and ionomycin. Under these conditions, CK18-specific cells were 
able to produce IFN-γ, although to a lesser extent than CMV-specific cells in donor 
HD37 (Figure 4C). 
The high intracellular perforin content of cytokeratin 18-specific cells observed 
previously (Table 1) suggested that they are cytolytic T lymphocytes (CTLs). We 
therefore isolated these cells from donor HD7 by multimer-guided FACS sorting 
and tested them ex vivo against peptide pulsed, HLA-A*0201-expressing T2 target 
cells. In contrast to CMV-specific CTLs sorted in parallel from the same donor, 
CK18-specific cells displayed no detectable cytotoxicity after 6 or 21 h (Figure 5 
and data not shown). 
Thus, although possessing a phenotype generally associated with immediate 
effector function, cytokeratin 18-specific CD8+ cells were unable to exert direct 
killing or to produce IFN-γ after peptide-specific stimulation, at least under the in 
vitro conditions tested. We conclude that these cells are apparently functionally 
impaired and represent a so far undescribed new subpopulation of peripheral 
CD8+ T cells. 
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Figure 5. CK18-specific CD8+ cells do not 
kill peptide-loaded targets ex vivo. CD8+ T 
lymphocytes from donor HD7 were sorted 
using multimers into non multimer-binding, 
CMV-specific and Ker-specific populations. 
Specific cytotoxicity was measured in a 
standard 6h 51Cr release assay using 
peptide-pulsed T2 target cells at the indicated 
effector to target ratios. 
 
 
 
 
 
 
Figure 6. CK18-specific CD8+ 
T cells express natural killer 
cell inhibitory receptors. 
PBMC from donors HD7 or 
HD37 were stained with (A) 
mAb against CD94/NKG2A, 
KIR2DL1, KIR2DL2 and ILT2, 
plus CD8APC-Cy7, and (B) 
mAb against KLRG1 followed 
by CD8PerCP and multimers 
A2/Ker-PE plus A2/CMV-APC 
as indicated in Methods. Dot 
plots are gated on CD8+ cells 
and results obtained for the 
CMV-specific and Ker-specific 
populations are shown for 
each donor. Data shown in (A) 
for HD7 and HD37 derive from 
separate experiments, and 
were reproduced at least two 
times. 
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CK18-specific CD8+ T cells express natural killer cell inhibitory receptors 
A possible explanation for the lack of appropriate functional responses of CK18-
specific CD8+ cells could be the cell-surface expression of inhibitory receptors for 
widespread ligands, eg. HLA molecules, found on natural killer (NK) cells and 
some subsets of CD8+ T cells. CD94/NKG2A and KIR2DL1 (p58.1) were indeed 
found to be expressed by most of the A2/Ker-binding cells from donors HD7 and 
HD37, respectively (Figure 6A). These receptors were present in only a small 
subpopulation of total CD8+ cells and were absent from the cell-surface of most of 
the CMV-specific cells in these two donors. We also detected uniform expression 
of the Ig-like transcript 2 (ILT2) by CK18-specific T cells, as well as the majority of 
the CMV-specific cells. Finally, all CK18-specific cells coexpressed the killer cell 
lectin-like receptor G1 (KLRG1), as did the CMV-specific cells from the same 
donor (Figure 6B), but not Melan-A-specific cells present in another healthy donor 
(data not shown). There was no staining using mAb directed against the inhibitory 
receptors KIR2DL2 (p58.2), KIR3DL1 (p70), ILT5 or NKRP1A on either CK18- or 
CMV-specific cells, whereas these two subpopulations were equally weakly 
recognized by a mAb directed against the activatory receptor 2B4 (Figure 6A and 
data not shown). Thus, A2/Ker-binding cells express a different pattern of 
inhibitory NK receptors than CMV-specific cells from the same donors, and this 
pattern is distinct among individuals, at least in the two donors tested. 
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Discussion 
 
Among the subpopulations of CD8+ peripheral T lymphocytes, CD45RA+  cells that 
lack the expression of markers CCR7, CD27 or CD28 have been shown to exert 
direct ex vivo redirected killing and to secrete inflammatory cytokines such as IFN-
γ or TNF-α after non- specific stimulation 1,4. Because of this immediate 
cytotoxicity and their poor ability to proliferate, in certain in vitro models at least, 
they have been thought to represent the final stage of CD8+ T-cell differentiation 
and have been called terminally-differentiated effectors. The cytolytic function of 
such cells has been confirmed in studies in which viral- (in primed healthy donors), 
or more rarely, tumor antigen-specific cells (in some tumor bearing patients), were 
detected by HLA-class I multimer staining combined with cell-surface phenotyping 
for CD45RA, CD27, CD28 or CCR7 and functional assessment 13,15,21,22. However, 
the variable proliferative capacity and phenotypic changes occasionally observed 
for CD8+ effectors upon stimulation suggest that this population might be more 
heterogeneous than initially assumed and could have functions other than merely 
representing a pool of cells “ready to kill” 12,18. In the present study, we have 
characterized a new antigen-specific subpopulation of CD8+ T cells which 
recognizes a peptide derived from the protein cytokeratin 18 and presented by 
HLA-A*0201. A2/Ker multimer-binding cells could be directly identified at a 
significant frequency in the PBMC of 5/33 HLA-A2+ healthy donors, apparently 
independent of age (at least, between 35 and 62) or sex, but were absent from all 
20 HLA-A2- controls tested (Figure 1 and data not shown). 
 
A2/Ker-binding cells have the distinct profile of antigen-experienced effectors i.e. 
possess a CD45RA+CD28-CCR7- phenotype and contain relatively few TREC, as 
expected from cells that have divided in vivo 26. However, in HD7 and HD37, 
differences in the expression of the markers CD45RA, CD27 and CD57 were 
observed, suggesting slightly different stages of differentiation for A2/Ker-binding 
cells in these two donors (Table 1). Since CK18-specific cells also express a 
significant level of intracellular perforin, it was unexpected to find that they were 
anergic to in vitro antigenic (peptide-specific) stimulation, in terms of IFN-γ 
production (mRNA and protein) and also of killing of peptide-loaded targets after 
cell-sorting (Figures 4 and 5). It was unlikely that this was due to low affinity, since 
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we observed that (i) the CK18 peptide binds readily to HLA-A*0201 and (ii) there 
was no response using titrated concentrations of peptide up to 100 μM (data not 
shown). In further intracellular staining experiments using whole PBMC of donors 
HD7 and HD37, we found no production of the cytokines TNF-α, IL-2, IL-4, and 
also no IL-10, upon peptide stimulation of the A2/Ker-binding CD8+ cells (data not 
shown). This indicates that they most probably do not belong to the Tc2 subset. 
Moreover, these cells were unable to proliferate in response to peptide stimulation 
and low dose hIL-2, whereas A2/CMV-binding cells from the same donors did 
divide after contact with the specific CMV peptide, as demonstrated in CFSE 
labeling experiments (data not shown). Thus, under these test conditions, CK18-
specific CD8+ T cells appeared to be unresponsive to antigen-specific stimulation, 
whereas IFN-γ production and a significant degree of cell division following 
activation by PMA/ionomycin, anti-CD3 mAb or PHA was observed (Figure 4C and 
data not shown). 
 
Different mechanisms could explain this impairment, including active 
immunoregulation by regulatory T cells or the expression of NK cell inhibitory 
receptors. It is known that effector CD8+ cells do express a large range of 
inhibitory (but also activatory) molecules. In mouse and human models, blocking of 
some of these receptors with specific antibodies has been reported to release 
effector function and induce target cell-killing 28-30. We found that CK18-specific 
cells carry several inhibitory receptors. Remarkably, the heterodimer 
CD94/NKG2A (for HD7) and KIRDL1 (HD37) were not expressed by autologous, 
functional, CMV-specific cells, and only by a fraction of the whole CD8+ T-cell 
population. These two inhibitory receptors have been reported to interact with 
HLA-E and HLA-C molecules, respectively. Moreover, ILT2 and KLRG1 were also, 
but not exclusively, present on the surface of CK18-specific cells from both 
donors. However, blocking antibodies against ILT2 (HP-F1, kindly provided by Dr. 
M. Lopez-Botet) and CD94/NKG2A (Y9, gift from Dr. A. Moretta) did not reveal 
reconstitution of specific antigenic peptide-stimulated IFN-γ production from 
A2/Ker-binding cells in total PBMC of HD7 and HD37. The broad expression of 
their ligands, in particular HLA-E, on PBMC might explain this result. Alternatively, 
NK receptors such as KIR2DL1 (for HD37), KLRG1, or others, could also 
participate in the downregulation of T-cell reactivity. Finally, CK18-specific CD8+ T 
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cells might exert an undefined function, similar to antigen nonspecific, CD8+CD28- 
peripheral T cells, which have been described to display immunosuppressive 
activities 31,32. The isolation of CK18-specific T-cell clones should support further 
functional studies. 
Our experiments do not exclude the possibility, however, that the cytokeratin 18 
peptide is an altered ligand or an antagonist peptide. Crossreactivity of self-ligand 
with virus-derived epitopes has been described 33,34, and experiments based on 
peptide analogues or combinatorial libraries could help to resolve the issue in this 
case 34,35. Nevertheless, the CK18 365-373 peptide described here constitutes a 
genuine, most probably relatively abundant HLA-ligand, which was found in HLA 
extracts obtained from different tumor cells such as fresh renal cell tumors 23 and 
an EBV-transformed cell line transfected with a CK18-encoding construct (S. 
Stevanović, unpublished data). 
Antigen nonresponsive CD8+ T cells have already been described in certain 
physiological situations. Using HLA-class I multimers, peripheral expansions of 
CD28- CMV- or EBV-specific T cells (up to 25% of the total CD8+ repertoire) have 
been observed in healthy donors of a very advanced age (>85) 36,37. Most of these 
cells are in fact anergic and dysfunctional, i.e. do not respond to peptide-specific in 
vitro stimulation but do respond to PMA/Ionomycin in terms of cytokine production, 
and in addition they also express KLRG1. A similar situation is observed in HIV 
patients, in which only a fraction of the viral epitope-specific T cells produces IFN-γ 
upon peptide stimulation 38. A low level of perforin expression was also observed 
in these cells 38,39. A population of tyrosinase-specific CD8+ T cells, as detected by 
multimer staining of PBMC from a melanoma patient, has also been reported to be 
anergic to ex vivo specific stimulation. These cells were CD45RA+CD27-CD28-
CD57+, consistent with a differentiated effector phenotype, but they neither killed 
antigen-presenting cells, nor did they produce IFN-γ or TNF-α, even after 
exogenous interleukin-2 was added to the assay 40. Finally, Melan-A-specific 
effector cells present in melanoma lesions are also unable to secrete IFN-γ upon 
antigenic challenge ex vivo, express variable amount of perforin and granzyme B, 
but regain functionality after short-term culture with IL2 and IL7 41. Thus, 
apparently dysfunctional CD8+ T cells can be detected during viral infection, tumor 
progression and in the elderly, all situations of possible chronic antigenic 
stimulation. A progressive functional impairment of virus-specific CTLs has been 
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reported to occur in persistent LCMV infection 42. It has also been hypothesized 
that accumulation of antigen-specific, dysfunctional CD8+ T cells could actually 
participate in a more extensive T-cell dysfunction 37,43. Some other mouse studies 
propose that the development and maintenance of similar, antigen-nonresponsive 
(i.e. tolerant) CD8+ T cells could be due to the absence of proper costimulatory 
signals 44-46. In this regard, it is interesting to note that cytokeratin 18 constitutes 
an intermediate filament protein expressed in normal single-layered epithelia such 
as liver, colon or kidney, and it is tempting to hypothesize that anti-CK18 effector 
CTLs should be tolerized under normal conditions. Why CK18-specific cells could 
be detected in some, but not all healthy individuals remains to be investigated. 
Recently, it has been reported that the protein is released during cell death, 
distinct forms being produced by apoptotic versus necrotic cells 47. Different 
individuals may differ in this respect. On the other hand, CK18 is a known tumor 
marker associated with malignancies of various origins, such as renal cell, bladder 
or breast carcinoma 23,48,49. Because the CK18-derived peptide was eluted from 
HLA molecules in kidney tumors, we are currently searching for CK18-specific 
cells in HLA-A2+ renal cell carcinoma patients. It is also known that autoantibodies 
recognizing the CK18 protein are produced in several abnormal physiological 
conditions, such as autoimmune hepatitis and nonallergic asthma 50,51. Thus, 
immune reactivity against the cytokeratin 18 protein develops under diverse 
apparently disease-associated circumstances. Investigations in relevant 
pathologies should help to characterize this newly-defined, self-specific CD8+ T-
cell subset further. 
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Summary 
 
T cells are central orchestrators and effectors of the adaptive immune system. 
CD8+ T cells that recognize peptide antigens presented on MHC class I molecules 
are believed to play a central role in fighting viral infections, intracellular pathogens 
and cancer. The use of recombinant peptide-HLA class I complexes that mimic the 
natural ligands of human CD8+ T cells should greatly facilitate the manipulation 
and analysis of such cells, allowing further insight in their biology and opening 
therapeutic applications. 
To permit the rapid access to cytotoxic CD8+ T cells with defined properties, 
artificial antigen presenting cells with defined MHC densities were devised that 
enable in vitro priming of high- or low-avidity effector T cells at will. High-avidity T 
cells required more stringent costimulatory conditions during priming but were 
clearly superior in recognizing tumor cells expressing antigen. The efficiency and 
high degree of control of such a system may be of great potential for future 
immunotherapeutic settings. 
Using fluorescent MHC I multimers to analyze T-cell responses during infection 
and in healthy individuals, it was found that these tools allow the detection of 
unconventional T cells that would have remained unidentified by the use of 
conventional methods.  
First, in a patient with congenital CMV infection, it was found that circulating 
functional CD4+ and CD8+ T cells specific for the same viral peptide bound to an 
HLA class I molecule can coexist. This unexpected finding will extend the view of 
T-cell responses against viral antigens and poses questions on the role of MHC 
class I restricted CD4+ T cells in vivo.  
Finally, the detailed ex vivo characterisation of another unexpected cell population 
was reported. These CD8+ T cells, found in a significant proportion of healthy HLA-
A2+ donors, are apparently specific for a peptide from the self-protein cytokeratin 
18. Albeit showing the phenotypical hallmarks of antigen-experienced effector 
CD8+ cells, these cells did neither lyse cognate target cells nor did they express 
any tested cytokine upon antigen recognition. These findings suggest that the 
subset of circulating human CD8+ T cells with the effector phenotype may be more 
heterogenous than previously thought and comprise cells without classical effector 
function and so far with unknown function. 
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Zusammenfassung 
 
T-Zellen stehen als Effektoren und Organisatoren im Zentrum des adaptiven 
Immunsystems. CD8+ T-Zellen, die Peptide auf MHC Klasse I erkennen, wird eine 
zentrale Rolle bei der Abwehr von Viren, intrazellulären Erregern und Krebs 
zugesprochen. Die Verwendung von rekombinanten Peptid-HLA I Komplexen, 
welche die natürlichen Liganden humaner CD8+ T-Zellen imitieren, sollte die 
gezielte Beeinflussung und Analyse solcher Zellen erleichtern. Dadurch werden 
neue Einsichten in Biologie und therapeutische Anwendung dieser Zellen erhofft. 
Um zytotoxische CD8+ T-Zellen mit definierten Eigenschaften zur Verfügung zu 
haben, wurden künstliche antigenpräsentierende Zellen mit kontrollierten MHC-
Dichten erdacht. Damit konnten in vitro gezielt hoch- oder niedrigavide Effektor-T-
Zellen generiert werden. Hochavide T-Zellen benötigten striktere kostimulatorische 
Bedingungen, waren jedoch bei der Erkennung von antigenpräsentierenden 
Tumorzellen überlegen. Das hohe Maß an Effizienz und Kontrolle dieses Systems 
könnte sich bei zukünftigen immuntherapeutischen Anwendungen auszahlen. 
Mittels fluoreszenter MHC I Multimere wurden T-Zellantworten während 
Infektionen und bei gesunden Spendern untersucht. Dabei zeigt sich, dass diese 
Werkzeuge den Nachweis von unkonventionellen T-Zellen ermöglichen, die mit 
gewöhnlichen Werkzeugen unerkannt bleiben würden.  
In einem Patienten mit kongenitaler CMV-Infektion wurde gezeigt, dass 
funktionelle CD4+ und CD8+ T-Zellen spezifisch für dasselbe virale Peptid auf HLA 
I im Blut koexistieren können. Diese unerwartete Entdeckung erweitert unser 
Wissen über T-Zellantworten gegen virale Antigene und wirft neue Fragen zur 
Funktion von MHC Klasse I restringierten CD4+ T-Zellen in vivo auf. 
Schließlich wurde die genaue ex vivo-Charakterisierung weiterer unerwarteter 
Zellen berichtet. Diese CD8+ T-Zellen, die in einem großen Anteil von gesunden 
HLA-A2+ Spendern auftreten, scheinen spezifisch für ein Peptid des 
körpereigenen Proteins Zytokeratin 18 zu sein. Trotz typischer Merkmale von 
antigen-erfahrenen Effektor-T-Zellen waren sie weder zur Lyse noch zur 
Expression von Zytokinen nach Antigenkontakt fähig. Diese Ergebnisse legen 
nahe, dass zirkulierende humane CD8+ T-Zellen mit Effektorphänotyp heterogener 
zusammengesetzt sind, als bisher angenommen wurde, und Zellen ohne 
Effektorstatus enthalten. Die Funktion solcher Zellen ist bisher unbekannt. 
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Abbreviations 
 
aAPC artificial antigen presenting cell  ILT immunoglobulin-like transcript 
Ab Antibody  Ker cytokeratin 
APC antigen presenting cell  KIR killer cell inhibitory receptor 
APC allophycocyanin  KLRG1 killer cell-lectin like receptor G1 
ATP adenosine-5'-triphosphate  LCL lymphoblastic cell line 
β2m beta-2-microglobulin  LCMV lymphocytic choriomeningitis virus 
BSA bovine serum albumin  LFA lymphocyte function associated antigen  
CD cluster of differentiation  MACS magnetically activated cell sorting 
CDR complementary-determining region  Mel Melan-A 
CFSE carboxyfluorescein diacetate, succinimidyl ester  MHC major histocompatibility complex 
CK Cytokeratin  NK natural killer 
CLIP class II-associated invariant-chain peptide   NKRP1A natural killer cell receptor P1A 
CMV cytomegalovirus  PAMP pathogen-associated molecular pattern 
CNS central nervous system  PBMC peripheral blood mononuclear cell 
CTL cytotoxic T lymphocyte  PBS phosphate buffered saline 
DC dendritic cell  PCR polymerase chain reaction 
DNA desoxyribonucleic acid  PE phycoerythrin 
DTH delayed-type hypersensitivity  PerCP peridinin chlorophyll protein complex 
EBV epstein barr virus  pH potentia hydrogenii 
EDTA ethylenediaminetetraacetic acid   PHA phytohaemagglutinin 
ELISA enzyme linked immunosorbent assay  PMA phorbol myristate acetate 
ELISPOT enzyme linked immunospot assay  pMHC peptide-major histocompatibility complex 
ER endoplasmic reticulum  Q-RT-PCR quantitative reverse transcriptase - PCR 
FACS fluorescent activated cell sorting  RAG recombination-activation gene 
FCS fetal calf serum  RNA ribonucleic acid 
FITC fluorescein isothiocyanate  RPMI roswell park memorial institute 
GALT gut associated lymphoid tissue   RT room temperature 
GCV Ganciclovir  TAP transporter associated with antigen processing  
HD healthy donor  TCR t-cell receptor 
HEPES 4-(2-Hydroxyethyl)-piperazin-1-ethansulfonsäure  TNF tumor necrosis factor 
HIV human immunodeficiency virus  TREC t-cell receptor excision circle 
HLA human leukocyte antigen    
HPLC high performance liquid chromatography    
ICAM intercellular adhesion molecule    
IFN Interferon    
Ig Immunoglobulin    
IL Interleukin    
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